patents.google.com

CN100586476C - A kind of therapeutic vaccine of Myostatin specific antibody and preparation method thereof - Google Patents

  • ️Wed Feb 03 2010
A kind of therapeutic vaccine of Myostatin specific antibody and preparation method thereof Download PDF

Info

Publication number
CN100586476C
CN100586476C CN200610104728A CN200610104728A CN100586476C CN 100586476 C CN100586476 C CN 100586476C CN 200610104728 A CN200610104728 A CN 200610104728A CN 200610104728 A CN200610104728 A CN 200610104728A CN 100586476 C CN100586476 C CN 100586476C Authority
CN
China
Prior art keywords
myostatin
vaccine
protein
gene
plasmid
Prior art date
2006-10-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200610104728A
Other languages
Chinese (zh)
Other versions
CN101057970A (en
Inventor
张英起
唐量
韩苇
李萌
薛晓畅
孟洁如
包春杰
郝强
李维娜
王增禄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fourth Military Medical University FMMU
Original Assignee
Fourth Military Medical University FMMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2006-10-13
Filing date
2006-10-13
Publication date
2010-02-03
2006-10-13 Application filed by Fourth Military Medical University FMMU filed Critical Fourth Military Medical University FMMU
2006-10-13 Priority to CN200610104728A priority Critical patent/CN100586476C/en
2007-10-24 Publication of CN101057970A publication Critical patent/CN101057970A/en
2010-02-03 Application granted granted Critical
2010-02-03 Publication of CN100586476C publication Critical patent/CN100586476C/en
Status Expired - Fee Related legal-status Critical Current
2026-10-13 Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明公开了一种Myostatin特异性抗体的治疗性疫苗及其的制备方法,利用人工合成DNA的方法获得了在N-端连接了Th细胞辅助表位TT830-844人myostatin C-末端区基因片段,其基因序列为TT-Ms,将合成的TT-Ms基因片段克隆至pQE30原核表达载体,构建了pQE-TT-Ms重组表达载体,利用PCR扩增Ms基因片段,构建了pQE-Ms重组表达载体;在大肠杆菌中表达了融合蛋白His-TT-Ms和His-Ms,对蛋白进行鉴定后作为myostatin的蛋白疫苗;将合成的TT-Ms基因片段克隆至pVAC1-cms基因疫苗专用质粒,构建了pVAC-TT-Ms重组质粒,体外进行了目的蛋白表达的鉴定,作为myostatin基因疫苗。本发明的方法所构建的Myostatin蛋白疫苗和基因疫苗,免疫健康成年BALB/c小鼠,可诱导出针对人myostatin分子的特异性抗体,免疫小鼠骨骼肌质量和力量明显提高。The invention discloses a therapeutic vaccine of Myostatin specific antibody and its preparation method. The human myostatin C-terminal region gene of TT 830-844 human myostatin C-terminal region is obtained by using the method of artificial DNA synthesis. fragment, whose gene sequence is TT-Ms, the synthetic TT-Ms gene fragment was cloned into the pQE30 prokaryotic expression vector, the pQE-TT-Ms recombinant expression vector was constructed, and the Ms gene fragment was amplified by PCR to construct the pQE-Ms recombinant expression vector Expression vector; the fusion proteins His-TT-Ms and His-Ms were expressed in Escherichia coli, and the protein was identified as a protein vaccine for myostatin; the synthetic TT-Ms gene fragment was cloned into the pVAC1-cms gene vaccine-specific plasmid, The pVAC-TT-Ms recombinant plasmid was constructed, and the expression of the target protein was identified in vitro as a myostatin gene vaccine. The Myostatin protein vaccine and gene vaccine constructed by the method of the present invention can induce specific antibodies against human myostatin molecules by immunizing healthy adult BALB/c mice, and the skeletal muscle mass and strength of the immunized mice are obviously improved.

Description

Therapeutic vaccine of a kind of Myostatin specific antibody and preparation method thereof

Technical field

The invention belongs to the medical biotechnology field, relate to that gene is synthetic, structure, the animal immune experiment of protein vaccine and gene vaccine, induce technology such as sero-fast vitro detection, therapeutic vaccine of particularly a kind of Myostatin specific antibody and preparation method thereof.

Background technology

Formation and the growth course that (myogenesis) refers to muscular tissue in the ontogenetic process takes place in muscle.The research that muscle takes place mainly comprises the growth of the formation of muscular tissue and Regulation Mechanism, muscular tissue and governing factor etc.The significance that research takes place muscle is: it is one of hot fields of developmental biology research that muscle takes place always, Skeletal Muscle Cell can be induced differentiation under condition of in vitro culture, there are objective morphology and molecular marker to distinguish simultaneously and breed or the own Skeletal Muscle Cell that breaks up, so the Regulation Mechanism research to the Skeletal Muscle Cell proliferation and differentiation is very important, for the differentiation mechanism research of muscle progenitor cell in the fetal development provides foundation; Muscle development and many muscle relevant diseases such as muscular dystrophy (MD), disuse muscle atrophy, tumor dyscrasia etc. are closely related, and research muscle can be pathogenesis research of muscle relevant disease and the diagnosis of muscle relevant disease, treats and provide fundamental basis; The research muscle development provides theoretical foundation for the animal breeding of animal husbandry meat.

1 Myostatin molecule and the active correlational study that suppresses

1.1 the discovery of Myostatin gene

1997, McPherron etc. have reported a kind of new transforming growth factor of cloning (transforming growth factor beta from mice skeletal cDNA library on " nature " magazine, TGF), by protein homology relatively, prove the newcomer of TGF-beta superfamily, be named as growth/differentiation factor 8 (

growth diferentiationfactor

8, GDF-8).Find when utilizing the function of gene knockout technical research GDF-8, the mice weight increase about 30% of GDF-8 gene knockout, skeletal muscle weight is 2~3 times of normal wild type mice, the number of skeletal muscle fiber exceeds 86% than wild-type mice, but does not find any phenotypic difference on other Growth Traits.Then the GDF-8 gene of other species such as rat, people, chicken, cattle, sheep, baboon obtains the clone in succession, and the research of its function has been obtained the result identical with mice.Confirm that GDF-8 has the negative regulation effect to the growth of skeletal muscle, so called after myostatin (being abbreviated as Mstn or Ms) again.

The Myostatin structure has the total typical characteristic of TGF-beta superfamily: 1. N-holds hydrophobic signal peptide sequence, but nationality plays secretion signal to cross over endoplasmic reticulum; 2. propetide has a glycosylation site; 3. be close to biologically active zone and form a protease processing site by 4 aminoacid (RSRR); 4. the C-end comprises the biologically active zone of 9 conservative cysteine, forms dimer by intermolecular disulfide bond.But myostatin and other members' of TGF-'beta ' family homology very low (being up to 45%) proves the newcomer of TGF-beta superfamily, does not belong to the subfamily of having found.Yet, the C-end regions, the member of myostatin sequence and other TGF-beta superfamilies has high homology, and its height correlation Protein G DF-11 also has this characteristic, the two has constituted the family of a uniqueness in the TGF-beta superfamily.

1.2 Myostatin gene structure and hereditary effect.

Confirmers' such as Gonzalez-Cadavid myostatin gene is positioned at chromosome 2q33.2, constitute by 3 exons and 2 introns,

introne

1 and

intron

2 are respectively 1.8kb and 2.4kb, contain three transcriptional start sites, and transcription product is the mRNA of 3.1kb.The Myostatin gene expression product is the ripe glycoprotein of 26KD, by 375 aminoacid codings, is secreted into outside the born of the same parents, and the secretion back forms precursor protein.Glycosylation site in the proparea is close to the protease processing site that biologically active zone is made up of 4 aminoacid (RSRR), and albumen is digested in the RSRR district.The N-end parts sequence of enzyme action (266 aminoacid) comprises the signal peptide sequence and the precursor protein sequence of hydrophobic secretion usefulness, C-end region (109 aminoacid) has 9 cysteine residues to form the structure of " Cys Knot ", form disulfide bond, constituting the myostatin maturation protein secretes to blood circulation, form dimer, with this proteic biological function of receptors bind performance with biologic activity.

1.3 the homology analysis of Myostatin gene

McPherron etc. [1]The C-end cDNA conservative with mice is the skeletal muscle cDNA library of probe screening different plant species, the cDNA sequence of having cloned rat, people, pig, cattle, sheep, chicken, turkey, baboon and Brachydanio rerio.Sequence analysis shows, the C-end mature peptide myostatin sequence homology of mice, rat, people, pig, chicken and turkey is 100%, baboon, cattle and sheep more only have the difference of 1~3 base, the homology of Brachydanio rerio and above-mentioned other animals is 88%, show myostatin sequence high conservative between different genera, may to have similar function between different genera relevant with myostatin albumen.

1.4 Myostatin gene expression and regulation

The in situ hybridization analysis finds that the myostatin gene all has expression in the embryo development procedure and the individual skeletal muscle of growing up.Early stage at fetal development, this expression of gene is confined to grow the muscle segment district of body segment, all expresses in the individual nearly all skeletal muscle of growing up.Utilize RT-PCR, Western-blotting technical research to show, myostatin also can detect its expression in the heart of period of embryo and adult, this albumen is present in the thin of cardiac muscular tissue and agree in Ye Shi fiber and the myocardial cell, myostatin up-regulated when myocardial infarction takes place, prompting myostatin tool in heart diseases such as the growth promoter of cardiac muscle and coronary heart disease has certain effect.Confirmation myostatin genes such as Ji also have a small amount of expression at animal adipose tissue, brain, tongue, the heart, lung, spleen, small intestinal, kidney, liver and bone marrow, and the expression of myostatin mRNA is also arranged in mammary gland.Show that the myostatin gene except that formation of regulation and control skeletal muscle and growth, also influences the growth and the differentiation of other protein involveds.

Ma etc. have cloned people myostatin gene and have comprised that 5 ' holds the total length 3.3kb fragment of regulatory region, find that the myostatin promoter sequence contains the growth response element to multiple material, comprise response elements such as glucocorticoid, androgen, thyroxin, MDF-1, MEF-2, NF-kB, and in external discovery, dexamethasone not only can strengthen the transcriptional activity of myostatin promoter in a kind of dose-dependent mode, and can strengthen endogenous myostatin expression of gene.Lang etc. have proved that the rising of myostatin in the body is relevant with IGF-I, II expression reduction, and the expression of myostatin is subjected to the just regulation and control that glucocorticoid raises under the stress state.Growth hormone (GH) has inhibitory action to myostatin, and Skeletal Muscle Cell is after adding GH, and myostatin expresses reduction.The GH receptor antagonist helps the myostatin up-regulated.

The expression of Myostatin is also closely related with the suffered load of muscle.The weight of muscle significantly descended after male adult rat carried out 17 days simulation spaceflights, and the muscle myostatin mRNA and the protein level of biceps femoris, quadriceps femoris, gastrocnemius are significantly higher than matched group simultaneously.Adult male bed 25 days is accompanied by the decline of lean body mass, muscle quantities, and blood myostatin concentration is higher than basic value 12%.Female Wistar rats is suspended in midair through 10 days hind legs, and sole of the foot flesh muscle weight in wet base descends 16%, and myostatin mRNA raises 110% simultaneously, and its protein level rises 37%.Above result shows under the situation that the muscle load reduces as aviation flight, bed, hind leg suspention etc., the decline of muscle quantities and myostatin mRNA and proteic level rising positive correlation, and training can reduce the expression of myostatin in the humans and animals body, improves muscle quality.

The human research finds that the myostatin level raises with advancing age, and middle age is than youngster height, and is the highest in 76~92 years old old women, and the content and the fat free body weight of serum myostatin are inversely proportional to; Be subjected to HIV to infect patient and healthy physiognomy ratio that muscle weight descends, the immunocompetence of myostatin all increases in its blood, the skeletal muscle, illustrate that myostatin is the attenuator of adult's Skeletal Muscle Growth, be the cause of disease that hiv infected patient skeletal muscle is become thin, will help to prevent and treat owing to human body increases the diseases such as amyotrophy that cause in age, AIDS to its further investigation.

1.5 the biological function of Myostatin

1.5.1 Myostatin is to the regulation and control of skeletal muscle

Studies show that myostatin C-stub area has important effect to the stability of its function, the inhibition zone is between aminoacid 42~115.Utilize gene knockout technology (knock-out) to make GDF-8 gene C-end biological activity zone disappearance of mice, obtain deficiency sudden change homozygote mice, this mice can normally survive and can procreate.Detect mice that its body weight finds homozygous mutation than the mice of heterozygote or wild type heavily about 30% (irrelevant) with sex, age.The muscle of sudden change homozygote mice shoulder and buttocks is obviously loose, remove skeletal muscle that skin finds whole health all than big many of the mice of wild type, the weight of monolithic muscle is about 2~3 times of wild-type mice, and fat weight does not have too big variation, so the increase of skeletal muscle weight is the main cause that causes the mutant mice weight increase.Further detect and find that the myofibrillar number of saltant mice skeletal has more 86% than wild-type mice, dna content exceeds 50% approximately, the hypertrophy (hyperplasia) that this shows the existing myocyte of reason of saltant mouse muscle hypertrophy also has myofibrillar hypertrophy (hypertrophy).

The function of Myostatin has also obtained checking blue cattle of Belgium (Belgian Blue) and Pierre Meng Teniu (Piedmontese).Belgian blue cattle through long-term hereditary and selection has very strong skeletal muscle, and is high by 29% than the common cattle of other kind.Cattle and mice Myostatin not only have very high homology (>95%) at amino acid levels, also are very conservative on function.The Belgian blue cattle of " two flesh symptom " and the myostatin gene of Pierre Meng Teniu are carried out the sequencing analysis result, the myostatin that finds Belgian blue cattle contains the disappearance (937aa-947aa) of 11 nucleotide at the 3rd exon, causes the frameshift mutation in protein active district; Owing to occur in after 7 aminoacid of C district initiating terminal, cause 102 aminoacid subsequently to lose (274aa-375aa), can not form ripe myostatin albumen; And a missense mutation takes place at the 3rd exon in the myostatin sequence of Pierre Meng Teniu, and the cysteine at protein active position is replaced by tyrosine, and the myostatin function is lost all or almost all as a result, causes the thin cattle meat rate to increase greatly.Spend myostatin gene delection in the cattle in vain in Belgian indigo plant, cause this gene reading frame to change, the molecular activity zone disappears, and the blue cattle of two flesh Belgium occurs.C becomes A in the

myostatin gene extron

1 of Piemonte cattle, and G becomes A in the

outer demonstration son

3, thereby causes two flesh cattle.Marcq etc. find when analyzing the possible genetic mechanism of the two flesh sheep of Belgian Texel, compare with common sheep, adopt the microsatellite marker of this gene flanking sequence to carry out linkage analysis shows though two flesh sheep myostatin gene coding regions do not have base difference, have a quantitative trait locus (QTL) to muscle development generation effect at two flesh sheep chromosome 2q distal areas, this gene locus (gene locus) is likely the myostatin gene.

Research to people myostatin gene shows that also this gene is relevant with the muscle growth growth.The myostatin expression of gene is higher than the normal person in HIV infects the patient of caused skeletal muscle atrophy, prompting myostatin abnormal gene expression may with some amyotrophic lateral sclerosis disease association.Schuelke etc. have reported 1 routine myostatin gene noncoding region g.IVS1+5 site homozygosity G → A sudden change and the heritability muscle hypertrophy child that causes this gene inactivation, thereby have confirmed that myostatin is regulating the developmental important function of human body Skeletal Muscle Growth.

1.5.2 Myostatin is to the influence of lipidosis

Myostatin gene delection also plays inhibitory action to lipidosis except influencing the skeletal muscle growth.Alexandra etc. [23]Experimental results show that, myostatin gene mutation homozygote mice and matched group are than the fatty minimizing 70% of average body, and therefore, one of reason that sudden change homozygote mice body weight raises is that lipidosis reduces, possible mechanism is that myostatin directly acts on fatty tissue, regulates its metabolic process; Another kind may be that the myostatin that the myostatin signal lacks in the remote-effects fatty tissue in the skeletal muscle suddenlys change, thereby influences lipid metabolism.Ji etc. compare myostatin knock out mice and wild type and also draw similar conclusion, and myostatin knocks out the Mus fat mass to be reduced, and leptin (Leptin) secretory volume also correspondingly reduces.

Myostatin is the excretory a kind of functional sugar albumen of Skeletal Muscle Cell, and it may take autocrine, paracrine, endocrine mode to bring into play the function of control Skeletal Muscle Growth.At present, how myostatin being controlled lipometabolic mechanism knows little about it.Recent a research report says that myostatin can be in the external differentiation that causes adipose cell (adipocytes).If myostatin also can directly act on adipose cell in vivo, it can play a role by system or original place so, and known myostatin mRNA has expression at fat, although its expression is than low slightly in skeletal muscle.Maybe may be that the mutation effect of myostatin is the indirect effect that the myostatin signal lacks in the skeletal muscle in the fatty tissue.For example, skeletal muscle tissue myostatin sudden change can change energy metabolism, to prevent the accumulation of body fat.Also have one may be that muscle lacks the secondary messager that the myostatin signal can influence hypothesis.They are discharged by muscle, act on fatty tissue.Still can not get rid of myostatin and act on the probability that other tissue such as CNS regulate fatty tissue by direct and indirect mode.Though the mice that an evidence of indirect mode is other heredity to change also has similar fatty build-up effect when muscle increases.For example, overexpression IGF-I or ski transgenic mice in fact all lack fat in the skeletal muscle.The muscle specificity knocks out the insulin receptor gene mice to be reduced with muscle quantities, can see adverse effect, i.e. fat accumulation increases.

Thoroughly set forth myostatin and regulate lipid metabolism mechanism in vivo and need analyze genetic manipulation animal (genetically), their myostatin signal pathway composition in skeletal muscle or fatty tissue by specificity ground tissue.External myostatin is combined with Act RIIA and Act RIIB, compare with the myostatin knock-out mice, express the negative form (adominant negative form) of Act RIIB dominance in the skeletal muscle, transgenic mice skeletal muscle sharply increases, preliminary analysis finds that the fat accumulation of these transgenic mices also descends, and this and myostatin match to the indirect action of fatty tissue.Be difficult to these data are made an explanation, although because skeletal muscle specificity myosin light chain promotes son/enhancer (promoter/enhancer) to can be used to drive the expression of mutant receptors, transgene expression also can detect in fatty tissue.Though the transgene expression level of fatty tissue is than much lower in the skeletal muscle, this low expression level may be to stoping the myostatin signal in the fat enough.

1.6 the mechanism of action of Myostatin

Muscle growth is the result of a series of complex processes, comprises expression that muscle generates transcription factor with active, the sarcoplast cell cycle withdraw from (withdrawal), the fusion of sarcoplast in myotube and the acquisition of an anti-apoptosis phenotype.Myostatin is brought into play function by the propagation that suppresses the muscle precursor, be likely by the differentiation of autocrine mechanism regulating muscle generative nature, and granulation promoting element (myogenin) is its important effective object.

1.6.1 Myostatin biological activity forming process

The TGF-beta superfamily member is synthetic with the form of precursor protein (precursor proteins) earlier, subsequently, after restriction enzyme site is processed in the mode of hydrolysis, becomes bioactive mature peptide and enters blood circulation.The cattle sarcoplast extract Western engram analysis of cultivating shows, the myostatin specific antibody has detected the existence and LAP (the latency-associated peptide of myostatin propetide (52kDa), 40kDa) form, this experiment obviously shows, myostatin synthetic and hydrolysis processing in sarcoplast really.According to TGF-β Proteolytic enzyme processing mechanism and the primary structure feature reported, the processing site of myostatin may just occur in the conservative RSRR residue.

1.6.2 Myostatin is to the regulation and control in sarcoplast cycle

The TGF-beta superfamily member is inhibited to the G1 phase in many mammalian cells cycle.This " stagnation " that occurs in a certain stage of cell cycle (arrest) it is believed that with cell cycle in many factor-related.Myostatin mainly brings into play inhibit feature in the G1 phase of sarcoplast growth, suppresses cell and enters the S phase.In addition, myostatin also influences sarcoplast and enters into the M phase from the G2 phase.And this process of inhibition is seemingly specific, because in similar test, the sudden change reorganization that the Pierre covers special cattle myostatin allele gene does not have similar inhibition behavior.In addition, cell culture test shows, the inhibitory action of myostatin can reverse after from cultivating system it being removed.As if the relevant cell growth property " stagnation " of Myostatin just by p21 specificity takes place regulates, because in the sarcoplast that myostatin handles, have only the level of p21 just to be regulated and control.In addition, p21 expresses increase, and slightly decline is relevant with the Cdk2 protein expression, and this is correlated with will further increase p21 and Cdk2 ratio, thereby causes the active reduction of Cdk2.Therefore, myostatin negative regulation cell cycle enters into the S phase from the G1 phase, has kept the quiescent condition of satellite cell.

1.6.3 the signal transduction path of Myostatin

The signal conduction of TGF-beta superfamily is the heterodimer complex by I type (T β RI) and II type (T β RII) receptor.The heterodimer of being made up of I type and II type serine/threonine phosphorylating kinase receptor homodimer in the signal conduction is compound-mediated.Smads is a TGF-signal beta transduction molecule in the Cytoplasm, can directly combine with DNA, and they can be with the TGF-signal beta directly by in the cell membrane transfered cell nuclear.Myostatin suppresses activity and the expression of MyoD just to the inhibition of sarcoplast differentiation by Smad3, make sarcoplast can not be differentiated to form myotube.Its mechanism is that the cysteine dimer of myostatin C-end combines with II type Ser/Thr protein kinase receptor (ActR IIB) earlier, and then combine with I type Ser/Thr protein kinase receptor (ActR IB), form an allos polymer at cell surface, by the kinase activity of II receptor, cause the phosphorylation in I receptor GS territory.Activatory I receptor can with temporary transient combination of MH2 of Smad2 in the endochylema and Smad3 molecule, and make the serine residue phosphorylation in C end SSXS district and activate.Smad4 with no phosphoric acid site forms polymer then, enter into nucleus, the phosphorylation of the serine/threonine residue of MyoD is obstructed, having blocked basic region combines with the E-box of sarcoplast control region, interference has active MyoD-E-box synthetic protein to form, thereby be suppressed to the myocyte to myocyte's differentiation and formation myotube, hindered the formation of muscle.

1.7 the progress of blocking-up myostatin function

Utilize the gene knockout technology, the mouse muscle fiber of gene targeting myostatin has tangible hypertrophy and increases slightly, and fat content obviously reduces with the growth at age.Except gene targeting, scientists proposes a kind of new technical thought, think it unnecessary to remove the myostatin gene, as long as with a kind of method it being carried out function disturbs, just can obtain good result, its imagination is: C-terminal is the dimer that connects by disulfide bond, has only two molecules just biologically active that links together.C-terminal dimer and other protein comprise its propetide in conjunction with constituting nonactive complex, the propetide that is similar to the TGF-'beta ' family in vivo with the effect of vitro inhibition TGF-β.If use transgene method, produce in animal body and a kind ofly can disturb the active protein of dimer, there is the myostatin dimer of physiologically active to reduce, it is better that muscle will be grown.For this reason, they have produced the transgenic mice of myostatin propetide overexpression according to this imagination, and mouse muscle development condition and health are observed and analyzed.These propetides combine with the C-end dimer of myostatin, formation does not have active polymer, can receive good effect yet, the transgenic mice weight increase 20%~110% of this myostatin precursor protein overexpression, other economic characters are interference-free, and mice can normally breed.

By contrast, the experimental result of U.S. John Hopkins University is better.They produce a kind of albumen that is follistatin with a kind of transgenic mice, this albumen can stop combining of myostatin and myocyte's receptor, thereby stop its restriction to muscle development, the muscle of this transgenic mice is 1~3 times of non-transgenic mice, the effect highly significant.Simultaneously, they also have a kind of imagination, have destroyed the bonded receptor with myostatin, so they have produced the transgenic mice of a kind of Act RIIB non-active structure territory albumen overexpression, the result receives good effect equally, and the weight ratio control mice of transgenic mice weighs 125%.Zhu etc. produce the transgenic mice of the proteolytic cleavage machining position point mutation of a kind of myostatin, because myostatin precursor site is cut, to discharge the bioactive peptide dimer, this albumen processing site mutation causes the dimeric generation obstacle of bioactive peptide, receives that equally mice weight increases the result of (20%-35%).

As if experiment in vitro confirms that the same C-that participates in adjusting myostatin of FLRG and GASP-1 holds dimeric activity.FLRG and GASP-1 combine with the myostatin in the blood in people and mice, show with the result of recombiant protein research, and these two kinds of albumen can both be with the C-end dimer combination of high-affinity with myostatin, and suppress its activity.What is interesting is that under the non-existent situation of C-end dimer, GASP-1 can directly combine with propetide.So far, still not about these molecules genetic information of biological function in vivo.

Another kind is exactly a myostatin antibody at the bioactive way of anti-myostatin directly.Immunity such as Whittemore have prepared the antibody of anti-myostatin, and handle the effect that adult mice is regulated adults muscle with checking myostatin with its, the result shows that the mice skeletal quantity with the myostatin antibody treatment of pharmacology dosage increases, and grip strengthens.This research has shown that first myostatin generates negative growth factor as skeletal muscle postnatal animal is worked, and prompting myostatin inhibitor can be used for clinical skeletal muscle growth inhibition treatment of diseases.In a word, blocking-up myostatin signal transduction path may be to increase the useful preparation of animal muscle growth, and is very meaningful in the treatment and the application in the agricultural of human muscle relevant disease.

1.8 Myostatin and muscle are diseases related

Myostatin as the muscle growth development inhibitor may with muscle diseases related have directly get in touch.Gonzalez-Cadavid etc. at first prove at HIV and infect to occur in cachectic patient bone flesh and the serum, and the myostatin expression is apparently higher than healthy people, have illustrated that the amyotrophy due to people's wasting diseases is relevant with the unconventionality expression of myostatin.Yarasheski etc. have studied the amyotrophy that shows with age growth in the normal population, and also the rising of myostatin is relevant in serum.Utilizations such as Zimmers can be handled the myostatin gene and circulate in vivo and express the animal model increase and confirm that high expressed myostatin albumen can bring out cachexia performances such as obviously becoming thin appears in animal, amyotrophy, eye socket depression in the body circulation.Discoveries such as Yamanouchi also have the expression of myostatin in the fibroblast of some infiltration wounds, think it may is because the inflammatory process that takes place at the anathrepsis commitment causes, and newborn skeletal muscle myostatin gene expression dose descends.Reardon etc. experiment showed, that myostatin is the secondary myofibrillar amyotrophy factor.Krik etc. find that by control experiment myostatin content is extremely low, illustrates that myostatin plays the negative regulation effect to anathrepsis in regenerated myotube part.

The pathology generation of myostatin participation muscular dystrophy that nearest research report is certain, (Duchennemuscular dystrophy DMD) blocks the amyotrophy symptom that the proteic expression of myostatin can be alleviated the mdx mice in the phenotype mice at mdx.Bogdanovich etc. utilize homemade mice myostatin protein antibodies treatment Du Shi muscular dystrophy model mice (DMD), and the treatment group is compared than control group mice, muscle quality, and muscular tension intensity obviously strengthens, and ill treatment mice symptom is obviously improved.Wagner etc. utilize the egg homozygote mice certainly and the mdx mice hybridization with DMD and BMD (Becker muscular dystrophy) phenotype of myostatin gene mutation, the mdx mice of screening myostatin sudden change in the offspring, these mices are strongr and be rich in muscle than mdx mice, show that blocking-up myostatin gene expression may alleviate muscular dystrophy patient's amyotrophy phenotype.The Myostatin antagonist can also be used to treating rhabdomyosarcoma.Experiments such as Sharma show that when myocardial infarction, the myocardial cell myostatin up-regulated around damaged part infers that myostatin plays an important role at myocardium pathology and physiological process mid-term.2004, Schuelke etc. have reported that 1 example causes the heritability muscle hypertrophy child case of gene inactivation, thereby confirmed the important function of myostatin in the human muscle cell adjusting and controlling growth because of myostatin gene noncoding region g.IVS1+5 site homozygosity G → A sudden change.

Discover myostatin gene delection mice (Mstn -/-Mice) not only show as muscle hypertrophy, hypertrophy but also follow athero to reduce.Confirm with fat and two kinds of model mices of diabetes subsequently, can effectively suppress athero and carbohydrate metabolism disturbance after the myostatin gene delection, provide new drug target for treating obesity and type ii diabetes.

2 therapeutic vaccines

1902, Wright was with heat-killed staphylococcus aureus vaccine therapy recurrent disease, and proposed the vaccine therapy theory and become the founder of modern vaccination therapy.Therapeutic vaccine (TherapeuticVaccine) is meant could break immunologic tolerance in chronic infection person's body! The new generation vaccine that reconstruction or enhance immunity are replied.Therapeutic vaccine can be eliminated pathogen or abnormal cell in diseased individuals inducing specific immunne response, and disease is treated, and is the new treatment means of antiviral, antineoplastic.Be mainly used in the disease of still not having effective medicine at present, as: chronic viral infection, allergy, tumor, Alzheimer thatch disease, diabetes, hypertension, obesity and rheumatic arthritis etc.Therapeutic vaccine as a kind of novel be the vaccine of purpose with the treatment, be a kind of supplementary means that improves the immunne response ability in the infectious disease comprehensive therapy, compare with preventative vaccine, the development of therapeutic vaccine will be many slowly.But monoclonal antibody is obtained immense success aspect the treatment disease, is indicating that the therapeutic vaccine that can induce antibody to produce in vivo has vast potential for future development.

2.1 the basic feature of therapeutic vaccine

Therapeutic vaccine as a kind of novel be the vaccine of main purpose with the treatment, all embody aspect mentality of designing, preparation means and the application technology diversification, stage construction and with modern molecular biology and the married characteristics of cytologic technology, the preventative vaccine that its complexity is traditional head and shoulders above.The application of therapeutic vaccine then is the individuality of the persistent infection of infective virus microorganism, use the use comparatively strict, that selection should be arranged, the vaccine composition can be done various combinations as required, be intended to break the immunologic tolerance of body, improve the immunne response of body, belong to the immunization therapy category, may certain side effect be arranged with immunologic injury.Yet diseases such as present many infectious disease, tumor still do not have effective medicine, and by contrast, the side effect of therapeutic vaccine is much smaller more than medicine.Therapeutic vaccine is as a kind of supplementary means that improves immunity in the infectious disease Comprehensive Treatment in addition, to some some disease of the mankind of still not having effective treatment means so far, has certain therapeutical effect as hepatitis B, leprosy, leishmaniasis bacterium, brucellosis etc.

Animal experiment shows and can treat following disease by producing high titre antibody in the inductor: induce the neutrality antibody of TNF-alpha specific by active immunity, can treat the joint of animal inflammation; Vaccine at angiotensin can be treated hypertension; Can treat Eosinophilia's disease that pathogen causes at the vaccine of IL-9; Vaccine at IL-5 can be treated asthma; Vaccine at N-methyl-D-aspartate receptor-1 (NMDAR1) can be treated apoplexy.In addition, at some gonadal hormone such as human chorionic gonadotropin (human chorionic gonadotro-pin, immunity HCG) can reduce the intravital hormonal readiness of women and reach contraceptive effect; Can treat prostate patient in late period at the vaccine of gonadotropin-releasing hormone (GnRH); Among the cancer of pancreas patient, the antibody that utilizes therapeutic vaccine to induce at gastrin (gastrin) can prolong patient's life late.

2.2 the classification of therapeutic vaccine

Therapeutic vaccine mainly is divided into following three classes by composition:

2.2.1 the compound reorganization therapeutic vaccine of protein

The structure of therapeutic vaccine target antigen or combination need the close target antigen that differs from traditional vaccine that has again, can arouse the functional immunity of sickened body and reply.Facts have proved and to transform in the face of protein vaccine from the three parts: modify at protein level, as lipoproteinization; In combination, carry out the compound of polyprotein and polypeptide coupling; On structure or configuration, transformed, as immobilization, crosslinked, the outer apparent conformation qualification etc. that reaches of structure.

As ideal immunogen; can comprise purpose antigen B cell epitope and self or external source t cell epitope in the antigen molecule simultaneously; can induce the body fluid or the cell immune response of out-degree high specific; play prevention or therapeutical effect from humoral immunization and cellular immune level, therefore can give wider protectiveness.But be hidden in the immunogenicity of the epi-position enhancement antigen of antigen molecule inside by design, general DR helper T cell epitope (pan-DR helper T cell epitopes, PADRE) or Universal T-cell epitopes (universal T epitope) combine with the common human leukocyte antigen-DR of crowd (HLA-DR) molecule with high-affinity, the less MHC of being subjected to limits.The key of preparation epiposition vaccine is to determine the specific polypeptide that can be discerned by immunocyte.Therefore the evaluation of epi-position is the first step that makes up epiposition vaccine.Identify that epi-position method commonly used has: 1. enzymatic isolation method; 2. use phage show peptide storehouse technology screening mimic epitope; 3. elution method: epi-position is eluted from MHC molecule or monoclonal antibody, check order; 4. synthetic overlapping peptide method; 5. use the computer software analysis whole genome, candidate's epitope peptide that prediction obtains is verified with experimental technique again, can identify epitope fast and accurately.Because the epitope polypeptide molecular weight is little, easily by intracellular proteasome degradation, can strengthen its immunogenicity by the whole bag of tricks.With B cell epitope and carrier protein such as bovine serum albumin (bovine serus albumin; BSA) or keyhole limpet hemocyanin (keyhole limpet hemocyanin; KLH) or phase coupling such as tetanus toxoid, the protection that is produced can be compared with macromole antigen.

In the malaria vaccine development; Birkett etc. are with the B cell epitope of multiple circumsporozoite protein and the t cell epitope immune human body in reorganization back of connecting with hepatitis B virus surface antigen or cAg; but excitating organism produces high-level antibody and Th1 type cellullar immunologic response, and behind the suitable adjuvant immunity human body Plasmodium falciparum challenge infection has been produced 50% protection.

2.2.2 cell vaccine

With the cell is that the vaccine of forming mainly contains tumor cell and dendritic cell (DC) vaccine.Can strengthen its immunogenicity with various accessory molecules modification tumor cells or DC, reach the purpose of treatment.Dendritic cell is the strongest antigen presenting cell of function in the body, can synthesize a large amount of MHC II quasi-molecules; Have picked-up and transport antigenic special film receptor; Can effectively absorb and handle antigen and migrate to the T cell compartment then, have the process of a maturing; Can activate infantilism T cell forcefully, a spot of antigen and a spot of dendritic cell promptly are enough to activated T cell.

DC can induce very strong primary immune response, and other antigen presenting cells such as macrophage and B cell can only activate the T cell that has been subjected to antigenic stimulus.The principal mode of antitumor immunity of organism reaction is a cellular immunization, and excitating organism produces the effective antitumour cellullar immunologic response, is to improve the key of exempting from curative effect, and the core of effective antitumour cell immune response is to produce CD8 +Cytotoxic T cell.Dendritic cell is generally by giant cell drink, receptor-mediated endocytosis and engulf 3 kinds of mode antigen uptaking, and can be directly to CD8 +CTL offers antigen, starts the killing activity of CTL cell.

At present, the tumor of using dendritic cell feedback therapy for treating comprises multiple myeloma, melanoma, carcinoma of prostate and colorectal cancer etc., and clinical practice I, II phase test have obtained challenging result.

2.2.3 nucleic acid vaccine

Nucleic acid vaccine is a kind of new generation vaccine that enjoys people to pay close attention in recent years.Nucleic acid vaccine comprises dna vaccination and RNA vaccine, can be caused that by coding the genetic fragment and the vector construction of the pathogen antigen of protective immunological reaction forms.Dna vaccination can be absorbed by host cell after intramuscular injection or particle gun import body, enters in the nucleus of host cell and is transcribed into mRNA, translates into protein again in endochylema.Part protein combines with MHC I quasi-molecule after degraded, and the surface of being offered cell is by CD8 +The receptor identification of T cell, and active cell poison T cell activity is killed and wounded target cell; And another part protein also can be secreted away, absorbed by antigen presenting cell as foreign protein again, in phagolysosome, be degraded into polypeptide, further combine with MHC II quasi-molecule, and offer cell surface by antigen presenting cell and discerned by the receptor of Th2 cell, cytokine by Th2 emiocytosis acts on the B cell then, and stimulates to produce the humoral immune reaction of antibody.

Compare with other vaccines, dna vaccination has many advantages: 1. offer the natural antigen form of immune system, do not have pathogen may duplicate and duplicate the morbific danger in back in vivo and do not have virulence reversion or sudden change.2. immunne response is comprehensive, can cause cellular immunization and humoral immunization simultaneously, and energy inducing cytotoxic T lymphocyte, thus infectious disease in the prevention cell.Researcher inserts vector plasmid with the DNA of encoding influenza virus A nucleoprotein, is injected in the Mus quadriceps femoris, successful production protectiveness CTL.Davis etc. also find, it is 100 times that the CTL of purification HBVenvAg immunity replys that the CTL of HBVenvAg genetic immunization replys.3. the single inoculation can be induced long-term or lifetime immunity.Davis etc. only inject a pin in the genetic immunization process.The good immunne response of 1 week back survey, and in 1 month, continue to raise, kept at least 17 months.4. produce easy rapidly, with low cost.5. need not cold preservation, be easy to storage and transport.6. be easy to carry out simultaneous inoculation, the possibility that designs new combined vaccine is provided at several antigen molecules of identical or different pathogen.7. nucleic acid vaccine can also improve baby's antibody response, promotes the elimination of intracellular antigen, prevents the inhibition of maternal antibody mediation.

Yet also there are a lot of weak points in dna vaccination: 1. stimulate a little less than the energy force rate natural infection of organism immune response.2. the expression of genes of interest is not ideal enough; 3. proteic expression can continue how long to remain further to study in the body, and the foreign aid DNA that 4. imports body has the potential danger of integration, and may cause the dysfunction of immune system itself after the dna immunization inoculation.Thereby further further investigation is carried out safety and long-term effect and is observed, and weighs the pros and cons of nucleic acid vaccine comprehensively, and its benefit of overall merit and danger are the new problems of current nucleic acid vaccine research.

Antigen presenting cell plays an important role in the inductive immunoreation of dna vaccination. but the main limitation of dna vaccination is that its immune efficient that causes is too low, the presenting cells that part is promptly only arranged seldom is by the foreign DNA transfection, therefore, how to improve dna vaccination to improve antigen presenting cell to the antigenic absorption of purpose with offer to become the direction of numerous scholar's research.To the encode gene of IgG Fc section and HBV e antigen gene such as You merges, and makes dna vaccination, and no matter this dna vaccination is at CD4 +Accessory cell, CD8 +Cytotoxic T cell, or all simple antigenic dna vaccination height of e in the B cell effect.Hung etc. have made up expression human papilloma virus 16

type E

7 albumen respectively and E7 is connected proteic dna vaccination with VP22, then with the vaccine intradermal vaccination in experiment mice, found that the E7-specific C D8 that the VP22/E7 dna vaccination produces +The E72 specific C D8 that the simple E7 dna vaccination of T cell produces +The T cell is high 50 times.The combination of multiple epitope is the immunogenic available strategy that improves dna vaccination.

Since nineteen ninety-five, the clinical trial of 6 kinds of people's dna vaccination has been ratified in audit of U.S. FDA biological product and research center, comprises the dna vaccination of acquired immune deficiency syndrome (AIDS), influenza, herpes simplex, hepatitis B, malaria and carcinoembryonic antigen.Because dna vaccination is a kind of new generation vaccine, present most of dna vaccinations are in the I clinical trial phase stage, and its main purpose is the safety and the immunogenicity of proof vaccine.The several years clinical observation does not find that as yet the dna molecular of vaccine can be incorporated in the chromosome or brings out the probability of autoimmune disease.It is encouraging that the malaria dna vaccination has entered the III clinical trial phase.

2.3 the mechanism of action of therapeutic vaccine

The therapeutic vaccine application is the individuality of infective virus, this moment, body was because of having the antigen of virus, but because immune response is partly low and shortcoming, can not support normal effect, therapeutic vaccine is offered immune system by different approaches with microbial antigen, remedy or the immune response of excitating organism (especially cytotoxicity, lymphocytic killing activity) thus reach the therapeutical effect of removing virus.Other has the scholar to think, behind receiving treatment property of the body vaccine, stimulates the T/B cell proliferation, and activating macrophage promotes NK cell killing tumor cell, thus performance potentiation.For example, bacillus calmette-guerin vaccine treatment tumor is treated tumor by the enhancing human body immunity system to the lethal effect of tumor cell exactly, makes patient's immune system to the aitiogenic while of new genetic recombinants, also repel and hit self similar cause of disease, thereby reach the effect of treatment.In addition, the mechanism of action of antigen-antibody complex type therapeutic vaccine may for: antibody to antigenic agglutination, form than macromole, easily engulfed and angtigen presentation; Antibody by the Fc receptors bind of Fc section and antigen presenting cell, has changed the process of angtigen presentation with after antigen combines, and more helps inducing antibody or CTL; Antigen-antibody complex can activate the release of multiple lymphokine, by the interaction between lymphokine, has more promoted antigenic offer and process and activate CTL or Th cell; The immunological network system can further play a role; Ag-Ab activating complement system helps the virus that cracking has or not film; Antigen-antibody complex itself can be used as adjuvant and strengthens immunogenicity of antigens.

In the immunoreation at exotic antigen, T cell and B cell are worked in coordination and could be produced antibody effectively: when being subjected to the exotic antigen immunity, specific B cell conjugated antigen produces initial activation signal.In addition, B cell endocytic antigen presents the complex of antigenic peptides and mhc class ii molecule on its surface.Usually, the B cell can not activate T HCell.Activate T HCell, dendritic cell is absolutely necessary, the dendritic cell antigen uptaking, and, activate T at the complex of its cell surface antigen-presenting peptide and MHC II quasi-molecule HCell.T after the activation HThe complex of antigenic peptides that cell recognition B cell surface presents and MHC II quasi-molecule causes other conversion of B cell proliferation, production of antibodies and antibody class.If lack T because of immunologic tolerance HThe synergism of cell so just can not produce antibody.In design process at the vaccine of oneself protein, if autoantigen merged with foreign protein or peptide carrier or be coupled at, just might walk around the TH cell tolerance: the specific B cell of autoantigen just can absorb this autoantigen and coupled carrier protein, and present the complex of carrier peptides and MHC II quasi-molecule on its surface, because T HCell does not have immunologic tolerance to carrier protein, thus can be activated, thus collaborative from the specific antibody of the B of antigenic specificity cell generation at autoantigen.

Compare with the T cell tolerance, it is much loose that Blymphocyte tolerance is wanted.In fact, in many cases, autospecific B cell occurs with normal frequency in vivo, if be subjected to antigen and T HThe combined effect of cell will be activated [88]So to many solubility oneself proteins, have its specific b cells strain in the body, especially when this albumen is not very expression more than needed especially like this.For this albuminoid or polypeptide, it is linked to each other with carrier protein, walk around the T cell tolerance, just might produce effective vaccine.Utilize this strategy, induced antibody response at multiple self hormone.

Embrane-associated protein and can induce B cellular immunization incapability with the albumen that the multivalence form exists, promptly reactionless to antigenic stimulus under normal conditions, have in addition can cause specific b cells clone's rejecting.Though can not stimulate disallowable specific b cells clone, by suitable immunization strategy, B cellular immunization incapability might be broken.The antigen of high copy number can be crosslinked with B-cell receptor effectively, provides intensive activation to stimulate, thereby break Blymphocyte tolerance.Someone is verified inductive more much better than than monomer TNF-α with the inductive antibody response of virus-like particle (VLPs) link coupled multicopy TNF-α.It can be possible thereby break Blymphocyte tolerance by level identification that this explanation makes antigen.This method may solve the problem of utilizing adjuvant in addition, because do not having can to induce strong antibody response under the situation of adjuvant with the link coupled antigen of VLPs.Not only in the mice body, have the antigenicity of height with the link coupled antigen of VLPs, and in human body, also have the antigenicity of height.50 μ g and the link coupled polypeptide of VLPs or chemical substance are not having just can to induce stronger antibody response in human body under the situation of adjuvant.Because latter's cost is lower, patient is acceptant and produce good compliance.

At present, there are about 500 kinds of biological medicines carrying out clinical research, nearly 100 kinds of vaccines wherein arranged, mainly at tumor and infectious disease.Seldom a part has been represented the first generation of this series products at the therapeutic vaccine of chronic disease and drug addiction, a kind of therapeutic vaccine at Alzheimer thatch disease has begun clinical trial, also has many therapeutic vaccine preclinical tests at autoantigen to make good progress.

2.4 the improvement strategy of therapeutic vaccine

The immunity of vaccine and pathomechanism more complicated, as the activated immunoreation of therapeutic vaccine, cell is protective or pathologic still indeterminate etc., causes the effect of vaccine therapy very unstable, desirable, and is ripe not enough in actual applications.Therefore how to bring into play immunomodulating, how to suppress persistent virus infection etc., these problems are prerequisites of development therapeutic vaccine, when the design therapeutic vaccine, select which kind of dominant antigen, immunostimulation and immunosuppressant all should compare and weigh as technical problems such as adjuvants.

This shows, can develop therapeutic vaccine from following several respects: 1. select best antigen conformation to inoculate enhance immunity originality; 2. develop the recombinant antigen between different virus, the chimeric antigen that virus and cytokine merge, virus antigen modifications etc. are to induce efficient immune; 3. antigen is produced albumen with the recombinant immune response gene and inoculate, so that discerned rapidly by CD8 or CD4 surface positive cell; 4. increase immune cofactor and use novel adjuvant; 5. use novel immunological technique, as dna immunization technique, antigenized antibody etc.; 6. MHC I class or the mhc class ii protein gene of directly will encoding introduced body, makes antigen, cytokine and other immune response gene products express processing in vivo, offers to immune system in the best condition.

Summary of the invention

The objective of the invention is to, therapeutic vaccine of a kind of Myostatin specific antibody and preparation method thereof is provided, for the muscle treating correlative diseases provides new medicine.

To achieve these goals, the technical solution adopted in the present invention is: a kind of therapeutic vaccine of Myostatin specific antibody, utilize artificial-synthetic DNA's method to obtain to have connected the auxiliary epi-position TT of Th cell at the N-end 830-844People myostatin C-end region genetic fragment, its gene order is TI-Ms, corresponding amino acid sequence is specific as follows:

Gly?Ser?Gln?Tyr?Ile?Lys?Ala?Asn?Ser?Lys?Phe?Ile?Gly?Ile?Thr?Glu

1 5 10 15

Ala?Ala?Ala?Glu?Phe?Asp?Phe?Gly?Leu?Asp?Cys?Asp?Glu?His?Ser?Thr

20 25 30

Glu?Ser?Arg?Cys?Cys?Arg?Tyr?Pro?Leu?Thr?Val?Asp?Phe?Glu?Ala?Phe

35 40 45

Gly?Trp?Asp?Trp?Ile?Ile?Ala?Pro?Lys?Arg?Tyr?Lys?Ala?Asn?Tyr?Cys

50 55 60

Ser?Gly?Glu?Cys?Glu?Phe?Val?Phe?Leu?Gln?Lys?Tyr?Pro?His?Thr?His

65 70 75 80

Leu?Val?His?Gln?Ala?Asn?Pro?Arg?Gly?Ser?Ala?Gly?Pro?Cys?Cys?Thr

85 90 95

Pro?Thr?Lys?Met?Ser?Pro?Ile?Asn?Met?Leu?Tyr?Phe?Asn?Gly?Lys?Glu

100 105 110

Gln?Ile?Ile?Tyr?Gly?Lys?Ile?Pro?Ala?Met?Val?Val?Asp?Arg?Cys?Gly?Cys

115 120 125

Ser?***?Val?Asp

130

Synthetic TT-Ms gene fragment clone to the pQE30 prokaryotic expression carrier, is made up the pQE-TT-Ms recombinant expression carrier, utilize pcr amplification Ms genetic fragment, made up the pQE-Ms recombinant expression carrier; At expression in escherichia coli fusion rotein His-TT-Ms and His-Ms, albumen is identified that the back is as the protein vaccine of myostatin;

Synthetic TT-Ms gene fragment clone to the special-purpose plasmid of pVAC1-cms gene vaccine, has been made up the pVAC-TT-Ms recombiant plasmid, and the external evaluation of having carried out the destination protein expression is as the myostatin gene vaccine.

Myostatin protein vaccine and gene vaccine that method of the present invention is constructed have been selected the special-purpose plasmid pVAC1-cms of gene vaccine for use during gene vaccine, make up the plasmid pQE30 that protein vaccine has been selected amalgamation and expression 6His for use, to improve the immunogenicity of expressing protein.The immune health BALB/c mouse of growing up can induce the specific antibody at people myostatin molecule, and immune mouse skeletal muscle mass and strength obviously improve.

Description of drawings

Fig. 1 is His-Ms expression, purification and qualification result.Wherein, figure (A) is that His-Ms obviously expresses in escherichia coli, and figure (B) is Ni affinity chromatography column purification destination protein His-Ms, and purity is more than 90%.Figure (C) is that the His-Ms fusion rotein behind the purification carries out the immunoblotting evaluation, finds that newborn protein band can combine with anti-GDF-8 multi-resistance and anti-His monoclonal antibody generation specificity.

Fig. 2 is His-TT-Ms expression, purification and qualification result.Wherein, figure (A) is that His-TT-Ms obviously expresses in escherichia coli, and figure (B) is Ni affinity chromatography column purification destination protein His-TT-Ms, and purity is more than 90%.Figure (C) is that the His-TT-Ms fusion rotein behind the purification carries out the immunoblotting evaluation, finds that newborn protein band can combine with anti-GDF-8 multi-resistance and anti-His monoclonal antibody generation specificity.

Fig. 3 is pVAC-TT-Ms plasmid purification and vivoexpression testing result.Wherein, figure (A) result shows pVAC-cms plasmid OD 260/ OD 280Be 1.78 (1.25ug/ul), pVAC-TT-Ms plasmid OD 260/ OD 280Be 1.82 (1.32ug/ul), illustrate that plasmid does not contain foreign material such as protein substantially, electrophoretic analysis shows that plasmid superhelix, spiral and linear band are distinct.Figure (B) is the plasmid purification transfection CHO cell, and RT-PCR result detects genes of interest to be had significantly and transcribe; Figure (C) detects destination protein at eukaryotic cell expression for the cellular immunization groupization.

Fig. 4 detects the immune serum antibody titer with ELISA: pVAC-TT-Ms recombiant plasmid immune animal result shows, in every group of 6 mices measuring, has antibody to produce (figure A) after 4 immunity are arranged, and the average antibody titre is 2 * 10 3More than (figure B).Myostatin protein vaccine immune animal result shows that in every group of 6 mices measuring, His-Ms organizes 2 * 10 2Dilution factor has antibody response (figure C) after 2 mouse immunes are arranged, and the average antibody titre is 2 * 10 2More than (figure E).And the His-TT-Ms group is 2 * 10 2Dilution factor has antibody response after 3 immunity are arranged, 2 * 10 3Dilution factor has antibody response (figure D) after 1 immunity is arranged, and the average antibody titre is 2 * 10 3More than (figure E).

Fig. 5 is the body weight change (figure A) of myostatin dna gene vaccine mice and the body weight change (figure B) of protein vaccine immune mouse.

Fig. 6 is the variation of immune mouse muscle quality.The result shows, compare with the normal control group, insert gene vaccine pVAC-TT-Ms group and protein vaccine His-TT-Ms group mice quadriceps femoris, gastrocnemius and the significantly increase of pectoralis major weight of TT epi-position, and outside His-TT group mice pectoralis major weight and matched group be significantly increased, though all the other two kinds of muscular tissue quadriceps femoris and gastrocnemius weight have increase, do not have significance.The pVAC-TT-Ms dna gene vaccine slightly is better than the His-TT-Ms protein vaccine to the influence of mice quadriceps femoris, gastrocnemius and pectoralis major weight.There is not significant difference between each group of the average weight of immune mouse abdominal cavity free-fat tissue.

Fig. 7 is an immune mouse muscular tissue metamorphosis.The result shows that gene vaccine pVAC-TT-Ms immune mouse and protein vaccine His-TT-Ms immune mouse quadriceps femoris cell have loose phenomenon.

Fig. 8 is that immune mouse forelimb grip changes.The result shows, the grip that can obviously strengthen the mice forelimb at gene vaccine and the protein vaccine of myostatin, compare with the normal control group, pVAC organizes no significant change, gene vaccine pVAC-TT-Ms group mice forelimb grip has on average increased by 30.9%, protein vaccine His-Ms group and His-TT-Ms group have increased by 26.6% and 29.6% respectively, and the strength that can obviously improve animal muscle at the vaccine immunity animal of myostatin is described.

The present invention is described in further detail below in conjunction with drawings and Examples.

The specific embodiment

The present invention utilize synthetic gene the method synthetic myostatin C-end region (133 aminoacid) gene order, made up gene vaccine and two kinds of therapeutic vaccines of protein vaccine at myostatin.Immunologic tolerance and reinforcement vaccine immunogenicity in order to break the myostatin vaccine have inserted the general Th cell epitope TT that activates the Th cytosis that has that derives from tetanus toxin at its N-end when making up myostatin protein vaccine and gene vaccine 830-844, to strengthen the immune effect of two kinds of therapeutic vaccines of myostatin.Utilize the antigen presentation carrier to the immunogenic influence of antigen, selected for use the gene epidemic disease to reach proteic immunogenicity when making up gene vaccine.The immune health BALB/c mouse of growing up, can induce at the special-purpose plasmid pVAC1-cms of the special Seedling of people myostatin molecule, make up protein vaccine and selected the plasmid pQE30 of amalgamation and expression 6His for use, to improve table property antibody, immune mouse skeletal muscle mass and strength obviously improve.Particular content is:

1 synthetic TT-Ms gene order

Synthetic N-end inserts the people myostatin mature peptide C-terminal gene sequence (133aa) of TT epi-position, and synthetic gene order is abbreviated as TT-Ms, and the TT-Ms corresponding amino acid sequence is specific as follows:

Gly?Ser?Gln?Tyr?Ile?Lys?Ala?Asn?Ser?Lys?Phe?Ile?Gly?Ile?Thr?Glu

1 5 10 15

Ala?Ala?Ala?Glu?Phe?Asp?Phe?Gly?Leu?Asp?Cys?Asp?Glu?His?Ser?Thr

20 25 30

Glu?Ser?Arg?Cys?Cys?Arg?Tyr?Pro?Leu?Thr?Val?Asp?Phe?Glu?Ala?Phe

35 40 45

Gly?Trp?Asp?Trp?Ile?Ile?Ala?Pro?Lys?Arg?Tyr?Lys?Ala?Asn?Tyr?Cys

50 55 60

Ser?Gly?Glu?Cys?Glu?Phe?Val?Phe?Leu?Gln?Lys?Tyr?Pro?His?Thr?His

65 70 75 80

Leu?Val?His?Gln?Ala?Asn?Pro?Arg?Gly?Ser?Ala?Gly?Pro?Cys?Cys?Thr

85 90 95

Pro?Thr?Lys?Met?Ser?Pro?Ile?Asn?Met?Leu?Tyr?Phe?Asn?Gly?Lys?Glu

100 105 110

Gln?Ile?Ile?Tyr?Gly?Lys?Ile?Pro?Ala?Met?Val?Val?Asp?Arg?Cys?Gly?Cys

115 120 125

Ser?***?Val?Asp

130

Synthetic two couples of primer P1 of PCR and P2 and P3 and P4.Primer P1 and P2 sport BamH I and Sal I respectively with the restriction enzyme site of 5 ' end and 3 ' end, to make up the pQE-Ms recombiant plasmid; Primer P3 and P4 sport BamH I and EcoR I respectively with 5 ' end and the 3 ' restriction enzyme site of holding, to finish the reorganization with the pVAC1-cms plasmid.

Primer1:5’CG?GGATCC?GATTTTGGTCTTGACTGTG?3’

Primer2:5’GCGTCGACTCATGAGCACCCACAGCG?3’

Primer3:5’CG?GGATCC?CAGTATATAAAAGCAAATTCT?3’

Primer4:5’GCGAATTCTCATGAGCACCCACAGCG?3’

2 gene clones and vector construction

2.1 the structure of recombiant plasmid pQE-TT-Ms and pQE-Ms

With BamH I and Sal I double digestion pQE30 plasmid, the big fragment of plasmid is connected with synthetic TT-Ms gene order, makes up pQE-TT-Ms; With BamH I and SalI double digestion pQE30 plasmid and PCR product Ms, connect again.Connect product transformed competence colibacillus cell DH5 α, the picking positive colony, overnight incubation in the LB culture medium is extracted plasmid DNA, identifies and dna sequence analysis through enzyme action.Correct person's called after pQE-Ms and pQE-TT-Ms will check order.

2.2 the structure of recombiant plasmid pVAC-TT-Ms

With pQE-TT-Ms is template, uses

synthetic primer

1 and

primer

2 pQE-TT-Ms 5 ' end and the 3 ' restriction enzyme site of holding are sported BamH I and EcoR I respectively.Pcr amplification: getting 1 μ L pQE30-TT-Ms plasmid is template, adds 10 * PCR buffer, 5 μ l, 25mmol/L MgCl 25Ml, 25mmol/

L

4 *

dNTPs

1 μ l, the

primer

2 of 25 μ M, 3 each 1 μ l add

TaqDNA polymerase

1 μ l, and water is supplied volume to 50 μ l.Carry out the PCR reaction then, the loop parameter of pcr amplification is: behind 95 ℃ of pre-degeneration 5min, circulate 30 times by following parameter: 94 ℃ of degeneration 1min, and 56 ℃ of annealing 1min, 72 ℃ are extended 1min, and last circulation is extended 10min for 72 ℃.

The PCR product reclaims the purpose fragment after separating with 1.5% agarose gel electrophoresis.Genetic fragment with BamH I and EcoR I double digestion pVAC1-cms plasmid and recovery, the big fragment of plasmid that reclaims is connected with the TT-Ms fragment, connect product transformed competence colibacillus cell DH5 α, the picking positive colony, overnight incubation in the LB culture medium, extract plasmid DNA, identify and dna sequence analysis that through enzyme action correct person's called after pVAC-TT-Ms will check order.

The abduction delivering of 3 recombiant proteins, purification and evaluation

3.1 the abduction delivering of recombiant protein

Recombiant plasmid pQE-TT-Ms and pQE-Ms transformed competence colibacillus cell BL21 (DE3), picking monoclonal overnight incubation, m seq is inoculated in the LB culture medium in 1: 100 ratio, cultivates 2 hours to logarithmic growth mid-term, OD for 37 ℃ 600nmValue was at 0.4~0.6 o'clock, and adding final concentration is the IPTG of 0.1mM, continued to cultivate 4 hours, collected thalline and carried out SDS-PAGE.

3.2 the purification of destination protein and evaluation

SDS-PAGE

Get that 500 μ l induce or not inductive bacterium liquid centrifugal collecting precipitation, 2 * load sample buffer (5% beta-mercaptoethanol that adds 30 μ l water and 30 μ l, 4%SDS, 20% glycerol, 100mmol/L TrisHCl, pH6.8,0.2% bromophenol blue), behind the vibration mixing, boil 5min in the boiling water, the centrifugal 5min of 12000rpm gets 10 μ l supernatant application of samples and concentrates glue in 15% separation gel and 6%.Voltage rose to 120V electrophoresis 1h after constant voltage 90V electrophoresis behind the last sample, sample entered separation gel.

The separation of inclusion body and preliminary purification

STE buffer (the 100mM NaCl that adds 10ml by 1 gram thalline, 50mM TrisHCl (pH8.0)) ratio is resuspended with thalline, in ice bath, carry out the ultrasonic bacterium of splitting then, ultrasonic time 5s, blanking time 10s, power 200W, broken 15min, 4 ℃ of centrifugal 15min, 12000rpm, abandon supernatant, collecting precipitation.With cleaning mixture (2MUrea, 2%TritonX-100, STE) washing precipitation (adding the 20ml cleaning mixture) by 1 gram thalline, 4 ℃ are stirred 1h, 4 ℃ of centrifugal 15min of 12000rpm abandon supernatant, regather precipitation.Repeat to wash twice.

To be deposited in degeneration buffer (8M carbamide, 10mM TrisHCl (PH 8.0), 100mM NaH 2PO 4) stirring at

room

3~5h, thoroughly dissolving.4 ℃ of centrifugal 10min of 12000rpm collect supernatant, with nickel affinity chromatography post (Ni post) purification destination protein.

With degeneration A liquid (8M Urea, 10mM TrisHCl (PH 8.0), 100mM NaH 2PO 4) abundant balance Ni post, behind the last sample, with the A liquid eluting foreign protein that contains the 30mM imidazoles, reuse contains the A liquid eluting destination protein of 250mMl imidazoles, collects eluting peak, the dialysis renaturation.

Protein immunoblot (Western blot)

After SDS-PAGE finishes, pull down gel, according to the Bio-Rad description of product, with close negative electrode one side of gel, close anode one side of cellulose nitrate (NC) film, transfering buffering liquid (25mmol/L Tris in pre-cooling, 192mmol/L Glycine, 20% methanol) middle 1 hour electrophoresis of 100V constant voltage, albumen is transferred on the NC film.After electrophoresis finishes, take out the NC film, cleaning mixture TBST (20mmol/L TrisHCl pH7.5,150mmol/L NaCl, 0.05% Tween20) clean the back immerse in the confining liquid (TBST that contains 2%BSA) 37

1 hour, the TBST room temperature is washed 3 times, each 5min, (dilution1: 1000), hatched 1 hour for 37 ℃, TBST washes 3 times to add the anti-people GDF-8 of rabbit polyclonal antibody (dilution 1: 1000) and mouse-anti His monoclonal antibody respectively, add goat anti-rabbit igg-AP and rabbit anti-mouse igg-AP respectively, hatched 1 hour for 37 ℃, TBST washes 3 times, reuse TBS (20mmol/L TrisHCl pH7.5,150mmol/LNaCl) wash 3 times, the NC film immerses in the colour developing liquid, room temperature lucifuge colour developing appropriate time, distilled water flushing cessation reaction.

Albumen dialysis renaturation

Collect the eluent of Ni post, adopt urea concentration gradient dialysis process dialysis purifying protein to H 2O solution.

The cultivation of 4 engineering bacterias

In the laboratory research stage, the applicant adopts triangle to shake bottle engineering bacteria is cultivated, and concrete steps are as follows: 1% activatory engineering bacteria is inoculated in the 500ml that contains 200ml LB culture medium and shakes in the bottle, and 37 ℃ of jolting 2.5h are to logarithmic growth mid-term, OD 600About 0.4~0.6 o'clock, adding final concentration was the IPTG of 0.1mM, continued to cultivate 4h, the centrifugal 15min of 4500rpm, and the collection thalline splits bacterium immediately or-20 ℃ of preservations are standby.

The amplification of 5 recombiant plasmid and purification

5.1 the amplification of recombiant plasmid

Recombiant plasmid pVAC-TT-Ms, transformed competence colibacillus cell DH5 α, picking monoclonal overnight incubation, m seq is inoculated in 10ml in 1: 100 ratio and contains in the antibiotic LB culture medium of zeocin and cultivate 8h, is inoculated in 200ml in 1: 100 ratio again and contains the antibiotic LB culture medium of zeocin, shake bacterium 25h, 200rpm, receives bacterium by 37 ℃.

5.2 results of host bacterium and alkaline lysis

With suitable rotary head in 4 ℃ with 4000rpm centrifugal 20 minutes, abandon supernatant, bacterial precipitation is resuspended among the ice-cold STE of 100ml.

The bacterial precipitation thing of the 500ml culture that Xian is crossed is resuspended in 10ml (18ml) solution I (10mmol/LEDTA (pH8.0), autoclaving 15min is stored in 4 ℃ for 50mmol/L glucose, 25mmol/LTrisCl (pH8.0)).The lysozyme soln (10mg/ml is dissolved in 10mmol/LTrisCl (pH8.0)) that adds the new preparation of 2ml, add again the new preparation of 20ml (40ml) solution II (0.2mol/LNaOH, 1%SDS).Cover tight bottle cap, slowly put upside down centrifuge bottle for several times, fully the mixing content is placed 5~10min in room temperature.Add the ice-cold solution III of 15nl (20ml) (5mol/L potassium acetate 60ml, glacial acetic acid 11.5ml, water 28.5ml).Seal bottleneck, shake centrifuge bottle for several times with the mixing content, two clearly demarcated liquid phases should no longer appear in this moment.Put and put 10min on ice, should form a white flocculent deposit.Formed precipitation should comprise and dyes body DNA, high molecular RNA and potassium-SDS-protein-membrane complex after 0 ℃ of placement.

With suitable rotary head in 4 ℃ with the centrifugal 15min of 4000rpm, do not open brake and make the stall of rotary head nature.If bacterial debris is adherent not tight, can the centrifugal once again 20min of 5000rpm, carefully supernatant is all forwarded to then in another bottle, discard the viscous liquid that remains in the centrifuge tube.Supernatant is filtered in the 250ml centrifuge bottle, adds the isopropyl alcohol of 0.6 volume, and fully mixing is placed 10min in room temperature.In room temperature centrifugal 15 minutes, reclaim nucleic acid with suitable rotary head with 500rpm.As in 4 ℃ centrifugal, salt also can living precipitation.Carefully outwell supernatant, open wide bottleneck inversion centrifuge bottle remaining supernatant is flow to end, room temperature deposits tube wall with 70% washing with alcohol.Pour out ethanol, use the pasteur pipet sucking-off that links with vacuum equipment to invest all drops of bottle wall, the bottle inversion is placed on the napkin, the trace ethanol of last remnants is waved totally, with 3mlTE (pH8.0) dissolving nucleic acid precipitation in room temperature.

5.3 the purification of plasmid (polyethylene glycol precipitation)

Nucleic acid solution is changed in the 15ml Corex pipe, adds the ice-cold 5mol/L LiCl of 3ml solution again, abundant mixing, with suitable rotary head under 4 ℃ with the centrifugal 10min of 10000rpm.Supernatant is transferred in another 30ml Corex pipe, added the isopropyl alcohol of equivalent, abundant mixing, usefulness SorvallSS34 rotary head (or commentaries on classics point suitable with it) with the centrifugal 10min of 10000rpm, is reclaimed sedimentary nucleic acid in room temperature.Carefully remove supernatant, open wide the mouth of pipe, pipe is inverted so that the drop of final residual flows to end.Precipitate and tube wall with 70% washing with alcohol in room temperature, flow to end ethanol, use the pasteur pipet that links to each other with vacuum equipment to inhale all drops that remove to invest tube wall, open wide the mouth of pipe and will manage inversion, on napkin, place a few minutes, so that last remaining trace ethanol evaporation totally.

Contain TE (pH8.0) dissolution precipitation of the pancreas RNase (20 μ g/ml) of no DNase with 500 μ l, solution is forwarded in the microcentrifugal tube, place 3min in room temperature.Add the 1.6mol/LNaCl that 500 μ l contain 13% (w/v) Polyethylene Glycol (PEG 8000), fully mix, with microcentrifuge in 4 ℃ with the centrifugal 5min of 12000g, to reclaim plasmid DNA.The sucking-off supernatant is with 400 μ l TE (pH8.0) dissolving plasmid DNA precipitation.With phenol, phenol: chloroform, chloroform are respectively taken out 1 time.Water is forwarded in another microcentrifugal tube, add 100 μ l 10mol/L ethanol ammoniums, fully mixing adds 2 times of volumes (about 1ml) ethanol, in room temperature placement 10min, in 4 ℃ with the centrifugal 5min of 12000g, to reclaim sedimentary plasmid DNA.Supernatant is removed in suction, adds 200 μ l and is in 4 ℃ with the centrifugal 2min of 12000g.Supernatant is removed in suction, opens wide the mouth of pipe, makes the trace ethanol evaporation totally.Measure OD with 500 μ l TE (pH8.0) dissolution precipitations dilution in 1: 100 (with TE (pH8.0)) back 260/ OD 280, the concentration (1OD of calculating plasmid DNA 260=50 μ g plasmid DNA/ml), then DNA is stored in-20 ℃.

The eukaryotic expression of 6 recombiant proteins

6.1 eukaryotic cell transfection and proteic expression

Chinese hamster ovary celI is cultivated based on 37 ℃ of 50ml/L CO with the low sugar DMEM that contains the 100ml/L hyclone 2Cultivating under the condition.Be inoculated in respectively in 6 orifice plates that contain coverslip with certain density, continue to cultivate 24~48h, make the cell attachment more than 80%.The sucking-off culture fluid, the DMEM that uses the serum-free antibiotic-free is with twice of cell flushing.Get 2 μ g DNA and be dissolved in the 100 μ l serum-free antibiotic-free DMEM culture fluid, be called A liquid.With 10 μ l LipofectAMINE TM2000 are dissolved in the DMEM culture fluid of 90 μ l serum-free antibiotic-frees, place 10min, are called B liquid.A, B two liquid are mixed, and incubated at room 30min makes it form the DNA-liposome complex.Add the DMEM culture fluid of 800 μ l serum-free antibiotic-frees in complex, mixing slowly drops in the cell of washing gently, in 37 ℃, 50ml/LCO 2Cultivate 7h under the condition.Transfection liquid is abandoned in suction, adds the DMEM culture fluid that 1ml contains the antibiotic-free of 200ml/L calf serum, in 37 ℃, 50ml/L CO 2After continuing under the condition to cultivate 36h, carry out the detection of destination protein transient expression.

7 make up the evaluation of vaccine

Identify the structure of protein vaccine with Western Blot.

After SDS-PAGE finishes, pull down gel, according to the Bio-Rad description of product, with close negative electrode one side of gel, close anode one side of cellulose nitrate (NC) film, transfering buffering liquid (25mmol/L Tris in pre-cooling, 192mmol/L Glycine, 20% methanol) middle 1 hour electrophoresis of 100V constant voltage, albumen is transferred on the NC film.After electrophoresis finishes, take out the NC film, cleaning mixture TBST (20mmol/L TrisHCl pH7.5,150mmol/L NaCl, 0.05% Tween20) clean the back immerse in the confining liquid (TBST that contains 2%BSA) 37

1 hour, the TBST room temperature is washed 3 times, each 5min, (dilution1: 1000), hatched 1 hour for 37 ℃, TBST washes 3 times to add the anti-people GDF-8 of rabbit polyclonal antibody (dilution 1: 1000) and mouse-anti His monoclonal antibody respectively, add goat anti-rabbit igg-AP and rabbit anti-mouse igg-AP respectively, hatched 1 hour for 37 ℃, TBST washes 3 times, reuse TBS (20mmol/L TrisHCl pH7.5,150mmol/LNaCl) wash 3 times, the NC film immerses in the colour developing liquid, room temperature lucifuge colour developing appropriate time, distilled water flushing cessation reaction.

The proteic detection of 8 eukaryotic expressions

8.1 cellular immunization groupization

Take out coverslip, PBS buffer rinsing 3 times, the acetone fixed cell 10min of pre-cooling, reuse PBS rinsing 3 times drips 10% calf serum at coverslip, and room temperature sealing 30min sops up.Drip behind the anti-people GDF-8 of the rabbit

polyclonal antibody

4 ℃ of refrigerators place spend the night or 37 ℃ hatch 60min, PBS shakes and washes 3 times, each 5min.Drip the goat anti-rabbit igg of FITC labelling, hatch 60min for 37 ℃, PBS shakes and washes 3 times, each 5min.Observe down and photograph in fluorescence microscope immediately after the glycerol mounting.Substitute an anti-negative control of doing with PBS.

8.2RT-PCR

The extraction of cell total rna: get the Chinese hamster ovary celI after the transfection, abandon the Trizol (4 ℃ of pre-coolings) that adds 1ml behind the culture fluid,, make the thorough cracking of cell with 5min at the bottom of the continuous purge culture bottle of rifle.With the cell pyrolysis liquid sucking-off little centrifuge tube of packing into, 4 ℃ of centrifugal 10min of 12000rpm get supernatant and place 5min in room temperature; Concuss behind the adding 0.2ml chloroform fully mixes it, and room temperature is placed 5min; 4 ℃ of centrifugal 15min of 12000rpm make it to be divided into water and organic facies is two-layer, carefully take out the water (the superiors) at RNA place, add the 0.5ml isopropyl alcohol, mixing gently, and room temperature is placed 10min; 4 ℃ of centrifugal 10min of 12000rpm abandon supernatant; Add 75% ethanol with the water preparation that does not contain the RNA enzyme, washing precipitation once; 4 ℃ of centrifugal 5min of 7500rpm abandon supernatant; Drying at room temperature RNA 10min; Getting water that 10 μ l do not contain the RNA enzyme adds in the centrifuge tube and dissolves RNA; The nucleic acid quantification analyser detects OD 260/ OD 280And rna content.

Reverse transcription reaction (RT): add total RNA (1 μ g), Oligo (dT) 1 μ l,

dNTP

2 μ l and the DEPC water that extracts in the reaction system of 12 μ l, be positioned over 5min in 65 ℃ of water-baths, place on ice then.The synthetic buffer of 4 μ l cDNA, 1 μ l DTT, 1 μ l RNaseOUT (40U/ml), 1 μ l DEPC water and 1 μ l reverse transcription are mixed (totally 8 μ l), add again in the above-mentioned 12 μ l reaction systems, and fully mix, hatch 30~60min for 50 ℃; Hatch 5min for 85 ℃; Add the RNaseH of 1 μ l and hatch 20min and can obtain cDNA in 37 ℃.The PCR reaction be preserved or be carried out immediately to the cDNA product can in-20 ℃.

PCR reaction: set up the reaction system of 50 μ l, add 10 * PCR reaction buffer, 5 μ l,

dNTP

3 μ l, upstream and downstream primer (

primer

2,3) each 1 μ l, cDNA product 10 μ l and

water

30 μ l respectively.Carry out the PCR reaction then, behind 95 ℃ of pre-degeneration 5min, add the TaqDNA polymerase.Circulate 30 times by following parameter: 94 ℃ of degeneration 1min, 56 ℃ of annealing 1min, 72 ℃ are extended 1min, and last circulation is extended 10min for 72 ℃.

The experiment of 9 immune animals

Myostatin gene vaccine and protein vaccine can induce in the mice body at this proteic antiserum, and the weight of animals of candidate gene vaccine and protein vaccine immunity increases, and the myocyte has loose phenomenon, and muscle quality and forelimb grip obviously increase.

9.1 laboratory animal

Laboratory animal is male BALB/c mouse, body weight 12~14g, and available from The Fourth Military Medical University's Experimental Animal Center, adaptability carries out immunity after feeding for 1 week.

9.2 mouse immune method

50 mices are divided into 5 groups, 10 every group, are respectively normal control group, pVAC group, pVAC-TT-Ms group, His-Ms group, His-TT-Ms group.

Protein vaccine His-Ms group and His-TT-Ms group immunizing antigen are to dialyse to H behind the purification 2O separates out albumen precipitation, dosage be 100 μ g/ only, animals of per two weeks immunity,

immunity

4 times, lumbar injection immunity, back 20 days pick test of last immunity.

Gene vaccine pVAC-TT-Ms group immunizing antigen is plasmid purification pVAC1-cms and purification and at external plasmid pVAC-TT-Ms that can expressing protein, dosage is 100 μ g/, injection in the quadriceps femoris, animals of per two weeks immunity,

immunity

4 times, last immunity sampling in back 20 days.The normal control treated animal is left intact.

9.3ELISA mensuration serum antibody titer

9.3.1ELISA measure dna gene vaccine mice serum antibody titer

The preparation of required solution:

Bag is cushioned liquid: Na 2CO 3(0.32g final concentration 0.015mol/L), NaHCO 30.59g (final concentration 0.035mol/L), pure water are settled to 200ml (pH 9.6).

Cleaning mixture: the PBS (pH 7.4) that contains 0.05% Tween-20.

Confining liquid: the cleaning mixture that contains 1% BSA.

Diluent: the cleaning mixture that contains 0.5% BSA.

Substrate buffer solution: Na 2HPO 412H 2O 1.84g, citric acid 0.51g, pure water are settled to 100ml (pH5.0).

Substrate colour developing liquid: OPD 8mg, 30%H 2O 230 μ l, substrate buffer solution 10ml.

Stop buffer: 1mol/L H 2SO 4

Operational approach:

Get 96 hole elisa plates, the supernatant soluble protein His-Ms that purification is dialysed to distilled water is cushioned liquid dilution (2~5 μ g/ml) with bag, adds in the plate hole (100 μ l/ hole), and 4 ℃ of bags are spent the night.Outwell coating buffer, add confining liquid, 37 ℃ of sealing 2h.Discard confining liquid, wash 6 times, each 3min with cleaning mixture.Add the antiserum (from 200 times) of 20 times of doubling dilutions, 1h is hatched for 37 ℃ in 100 μ l/ holes.Discard antiserum, wash 6 times, each 3min with cleaning mixture.Two of the goat-anti rabbit of adding HRP labelling resists, and 1h is hatched for 37 ℃ in 100 μ l/ holes.Discard two and resist, wash 6 times, each 3min with cleaning mixture.Add substrate colour developing liquid, 100 μ l/ holes, 37 ℃, colour developing 10~20min.Add stop buffer, 100 μ l/ holes, cessation reaction.The microplate reader reading is measured the light absorption value of every hole at 450nm.

9.3.2 cell ELISA is measured protein vaccine immune serum antibody titer

Chinese hamster ovary celI with 0.25% trypsinization after, adjusting cell concentration is 1.0 * 10 6/ ml adds 96 porocyte culture plates, 37 ℃, 5% CO with 200 μ l holes 2Cultivate 24h in the incubator, plasmid pVAC-TT-Ms and pVAC transfectional cell after the abundant adherent growth of 80% cell, method is the same.Behind the transfection 36h, inhale and to remove culture fluid, (PBS prepares, pH7.4) the fixing 20min of room temperature, PBS hole flushing 3 times with 0.025% glutaraldehyde for 37 ℃ of dry backs.Every hole adds 200 μ l and contains 3% H 2O 2PBS, room temperature reaction 20min, PBS hole flushing 3 times.Add different dilution test serums in the cell envelope hole respectively, every hole 200 μ l establish multiple hole, negative control, and 37 ℃ of incubator reaction 1h wash 3 times with washing liquid.Add 1: 10000 biotinylated goat anti-mouse igg antibody, every hole 200 μ l, 37 ℃ of reaction 1h, hole flushing 3 times dries.Add 1: 200 Avidin horseradish peroxidase, every hole 200 μ l, 37 ℃ of reaction 30min, hole flushing 3 times.Add OPD-H 2O 2Substrate 200 μ l, 37 ℃ of lucifuge reactions add 2M H 2SO 4Cessation reaction.Microplate reader is surveyed OD 490The nm value.

9.4 serum conventional index assay method

Automatic clinical chemistry analyzer detects the serum index: total protein (TP), albumin (ALB), globulin (GLB), blood urea nitrogen (BUN), blood glucose (GLU), cholesterol (CHO), triglyceride (TG), creatine kinase (CK).Detection kit is all purchased and is built up bio-engineering research institute in Nanjing.

9.5 skeletal muscle morphological analysis method

9.5.1 skeletal muscle groupization

Muscular tissue is separated, at fixative (10% neutral formalin, 50mmol/L PBS, pH 7.2) in 4 ℃ of fixing 24h, fixing back fully is the position section of protuberance in the middle of flesh, places solution (5% sucrose, 50mmol/L PBS, pH7.2) in 4 ℃ spend the night the dehydration of cold 50% acetone, place

pure acetone dehydration

2 times, dimethylbenzene is transparent, waxdip, paraffin (54 ℃~56 ℃) embedding, section, HE (hematoxylin and eosin) dyeing, microscopic examination.

3.5.2 muscle fiber cross-sectional area statistics

Utilize Scion Image 4.02 softwares (http://www.scioncorp.com), press Lee etc. [18]Report has carried out statistical analysis to the area of muscle fiber cell.

9.6 grip strength testing method

With reference to Peled-Kamar etc. [116]Reported method is tightly tied up the rope of a diameter 2mm in liftoff 80cm eminence, allows the mice forelimb hold rope, picks up counting, touch rope to hind leg till, surpass 10s if forelimb and hind leg are held the rope time simultaneously, be once successful grip strength testing.1d and preceding 4d have carried out twice test to its forelimb grip before mice is put to death, and 3 repetitions are arranged at every turn, and every mice recurrence interval time is consistent as far as possible.

9.7 data statistics is handled

Carry out statistical disposition with 2000 pairs of data of surveying of Excel, (x ± SD) expression, data are organized a t check to experimental result with mean ± standard deviation.

The constructed Myostatin vaccine of the present invention can induce in the mice body at this proteic antiserum, and immune mouse makes mice skeletal quality and strength obviously improve.

Synthetic TT-Ms gene order

Gly?Ser?Gln?Tyr?Ile?Lys?Ala?Asn?Ser?Lys?Phe?Ile?Gly?Ile?Thr?Glu

1 5 10 15

Ala?Ala?Ala?Glu?Phe?Asp?Phe?Gly?Leu?Asp?Cys?Asp?Glu?His?Ser?Thr

20 25 30

Glu?Ser?Arg?Cys?Cys?Arg?Tyr?Pro?Leu?Thr?Val?Asp?Phe?Glu?Ala?Phe

35 40 45

Gly?Trp?Asp?Trp?Ile?Ile?Ala?Pro?Lys?Arg?Tyr?Lys?Ala?Asn?Tyr?Cys

50 55 60

Ser?Gly?Glu?Cys?Glu?Phe?Val?Phe?Leu?Gln?Lys?Tyr?Pro?His?Thr?His

65 70 75 80

Leu?Val?His?Gln?Ala?Asn?Pro?Arg?Gly?Ser?Ala?Gly?Pro?Cys?Cys?Thr

85 90 95

Pro?Thr?Lys?Met?Ser?Pro?Ile?Asn?Met?Leu?Tyr?Phe?Asn?Gly?Lys?Glu

100 105 110

Gln?Ile?Ile?Tyr?Gly?Lys?Ile?Pro?Ala?Met?Val?Val?Asp?Arg?Cys?Gly?Cys

115 120 125

Ser?***?Val?Asp

130

Claims (3)

1.一种Myostatin特异性抗体的治疗性疫苗,其特征在于,将合成的TT-Ms基因片段克隆至pQE30原核表达载体,构建pQE-TT-Ms重组表达载体,利用PCR扩增Ms基因片段,构建pQE-Ms重组表达载体;在大肠杆菌中表达融合蛋白His-TT-Ms和His-Ms,对蛋白进行鉴定后作为myostatin的蛋白疫苗;1. a therapeutic vaccine of Myostatin specific antibody is characterized in that, the synthetic TT-Ms gene fragment is cloned into pQE30 prokaryotic expression vector, constructs pQE-TT-Ms recombinant expression vector, utilizes PCR to amplify Ms gene fragment, Construct the pQE-Ms recombinant expression vector; express the fusion proteins His-TT-Ms and His-Ms in E. coli, and identify the protein as a protein vaccine for myostatin; 或将合成的TT-Ms基因片段克隆至pVAC1-cms基因疫苗专用质粒,构建pVAC-TT-Ms重组质粒,体外进行目的蛋白表达的鉴定,作为myostatin基因疫苗;Or clone the synthetic TT-Ms gene fragment into the pVAC1-cms gene vaccine special plasmid, construct the pVAC-TT-Ms recombinant plasmid, carry out the identification of the target protein expression in vitro, and use it as the myostatin gene vaccine; 所述的TT-Ms基因片段对应的氨基酸序列具体如下:The amino acid sequence corresponding to the TT-Ms gene fragment is specifically as follows: Gly Ser Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr GluGly Ser Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu 1               5                   10                  151 5 10 15 Ala Ala Ala Glu Phe Asp Phe Gly Leu Asp Cys Asp Glu His Ser ThrAla Ala Ala Glu Phe Asp Phe Gly Leu Asp Cys Asp Glu His Ser Thr             20                  25                  3020 25 30 Glu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu Ala PheGlu Ser Arg Cys Cys Arg Tyr Pro Leu Thr Val Asp Phe Glu Ala Phe         35                  40                  4535 40 45 Gly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn Tyr CysGly Trp Asp Trp Ile Ile Ala Pro Lys Arg Tyr Lys Ala Asn Tyr Cys     50                  55                  6050 55 60 Ser Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His Thr HisSer Gly Glu Cys Glu Phe Val Phe Leu Gln Lys Tyr Pro His Thr His 65                  70                  75                  8065 70 75 80 Leu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys Cys ThrLeu Val His Gln Ala Asn Pro Arg Gly Ser Ala Gly Pro Cys Cys Thr                 85                  90                  9585 90 95 Pro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly Lys GluPro Thr Lys Met Ser Pro Ile Asn Met Leu Tyr Phe Asn Gly Lys Glu             100                 105                 110100 105 110 Gln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val Asp Arg Cys Gly CysGln Ile Ile Tyr Gly Lys Ile Pro Ala Met Val Val Asp Arg Cys Gly Cys        115                120                 125115 120 125 Ser***Val AspSer***Val Asp 130。130. 2.如权利要求1所述的特异性抗体的治疗性疫苗,其特征在于,所述的TT-Ms基因片段是利用人工合成DNA的方法获得了在N-端连接了Th细胞辅助表位TT830-844的人myostatin C-末端区基因片段。2. The therapeutic vaccine of specific antibody as claimed in claim 1, is characterized in that, described TT-Ms gene fragment utilizes the method for artificially synthesized DNA to obtain at N-terminus connected Th cell helper epitope TT 830-844 human myostatin C-terminal region gene fragment. 3.实现权利要求1所述的人Myostatin特异性抗体的治疗性疫苗的制备方法,其特征在于,该方法制备myostatin的蛋白疫苗或myostatin基因疫苗的步骤分别如下:3. realize the preparation method of the therapeutic vaccine of human Myostatin specific antibody described in claim 1, it is characterized in that, the method prepares the protein vaccine of myostatin or the step of myostatin gene vaccine respectively as follows: 一、myostatin的蛋白疫苗制备1. Protein vaccine preparation of myostatin 1)重组质粒pQE-TT-Ms和pQE-Ms的构建1) Construction of recombinant plasmids pQE-TT-Ms and pQE-Ms 用BamH I和Sal I双酶切pQE30质粒,质粒大片段与合成的TT-Ms基因序列连接,构建pQE-TT-Ms;用BamH I和Sal I双酶切pQE30质粒和PCR产物Ms,再进行连接;连接产物转化感受态细胞DH5α,挑取阳性克隆,于LB培养基中培养过夜,提取质粒DNA,经酶切鉴定和DNA序列分析;将测序正确者命名为pQE-Ms和pQE-TT-Ms;Digest the pQE30 plasmid with BamH I and Sal I, and connect the large fragment of the plasmid to the synthetic TT-Ms gene sequence to construct pQE-TT-Ms; use BamH I and Sal I to digest the pQE30 plasmid and the PCR product Ms, and then proceed Ligation; the ligation products were transformed into competent cells DH5α, positive clones were picked, cultured overnight in LB medium, plasmid DNA was extracted, identified by enzyme digestion and DNA sequence analysis; the correct sequencing was named pQE-Ms and pQE-TT- Ms; (2)重组蛋白的诱导表达、纯化与鉴定(2) Induced expression, purification and identification of recombinant proteins 1)重组蛋白的诱导表达1) Induced expression of recombinant protein 重组质粒pQE-TT-Ms和pQE-Ms转化感受态细胞BL21或DE3,挑取单克隆培养过夜,次日清晨,按1∶100的比例接种于LB培养基中,37℃培养2小时至对数生长中期,OD600nm值在0.4~0.6时,加入终浓度为0.1mM的IPTG,继续培养4小时,收集菌体进行SDS-PAGE;Recombinant plasmids pQE-TT-Ms and pQE-Ms were transformed into competent cells BL21 or DE3, and single clones were picked and cultured overnight. In the morning of the next day, they were inoculated in LB medium at a ratio of 1:100, and cultured at 37°C for 2 hours until In the middle growth stage, when the OD600nm value is 0.4-0.6, add IPTG with a final concentration of 0.1mM, continue to cultivate for 4 hours, and collect the bacteria for SDS-PAGE; 2)目的蛋白的纯化与鉴定2) Purification and identification of target protein SDS-PAGESDS-PAGE 取500μl诱导或未诱导的菌液离心收集沉淀,加入30μl水及30μl的2×载样缓冲液,载样缓冲液的配方为:5%β-巯基乙醇,4%SDS,20%甘油,100mmol/L Tris·HCl,pH6.8,0.2%溴酚蓝,振荡混匀后,沸水中煮5min,12000rpm离心5min,取10μl上清加样于15%分离胶和6%浓缩胶,上样后恒压90V电泳,样品进入分离胶后电压升至120V电泳1h;Take 500 μl of induced or uninduced bacterial liquid and centrifuge to collect the precipitate, add 30 μl of water and 30 μl of 2× loading buffer, the formula of loading buffer is: 5% β-mercaptoethanol, 4% SDS, 20% glycerol, 100mmol /L Tris·HCl, pH6.8, 0.2% bromophenol blue, shake and mix well, cook in boiling water for 5min, centrifuge at 12000rpm for 5min, take 10μl supernatant and add the sample to 15% separating gel and 6% stacking gel, after loading Constant voltage 90V electrophoresis, after the sample enters the separation gel, the voltage rises to 120V electrophoresis for 1h; 包涵体的分离和初步纯化Isolation and initial purification of inclusion bodies 按1克菌体加入10ml的STE缓冲液的比例将菌体重悬,该STE缓冲液的配方为:100mM NaCl,50mM Tris·HCl,pH8.0,然后于冰浴中进行超声裂菌,超声时间5s,间隔时间10s,功率200W,破碎15min,4℃离心15min,12000rpm,弃上清液,收集沉淀物,按1克菌体加入20ml洗涤液洗涤沉淀,4℃搅拌1h,12000rpm 4℃离心15min,弃上清液,再收集沉淀,重复洗两次;Resuspend the bacteria according to the ratio of adding 1 gram of bacteria to 10ml of STE buffer. The formula of the STE buffer is: 100mM NaCl, 50mM Tris HCl, pH8.0, and then perform ultrasonic cracking in an ice bath. 5s, interval time 10s, power 200W, broken for 15min, centrifuged at 4°C for 15min, 12000rpm, discarded the supernatant, collected the precipitate, added 20ml of washing solution to wash the precipitate according to 1g of bacteria, stirred at 4°C for 1h, centrifuged at 12000rpm for 15min at 4°C , discard the supernatant, then collect the precipitate, and repeat the washing twice; 将沉淀物在变性缓冲液室温搅拌3~5h,彻底溶解,12000rpm 4℃离心10min,收集上清,用镍亲和色谱层析柱,纯化目的蛋白,变性缓冲液配方:8M尿素,PH 8.0的10mMTris·HCl,100mM NaH2PO4Stir the precipitate in the denaturing buffer at room temperature for 3-5 hours, dissolve it thoroughly, centrifuge at 12000rpm at 4°C for 10min, collect the supernatant, and use a nickel affinity chromatography column to purify the target protein. Denaturing buffer formula: 8M urea, pH 8.0 10mM Tris HCl, 100mM NaH 2 PO 4 ; 用变性A液充分平衡色谱层析柱,上样后,用含30mM咪唑的A液洗脱杂蛋白,再用含250mM咪唑的A液洗脱目的蛋白,收集洗脱峰,透析复性,变性A液的配方为:8M Urea,PH 8.0的10mM Tris·HCl,100mM NaH2PO4Fully equilibrate the chromatographic column with denatured solution A. After loading the sample, use solution A containing 30mM imidazole to elute the impurity protein, then use solution A containing 250mM imidazole to elute the target protein, collect the eluted peak, dialyze for renaturation, denature The formula of liquid A is: 8M Urea, 10mM Tris HCl at pH 8.0, 100mM NaH 2 PO 4 ; 蛋白免疫印迹western blot SDS-PAGE结束后,拆下凝胶,将凝胶靠近阴极一侧、硝酸纤维膜靠近阳极一侧,在预冷的转移缓冲液中100V恒压1小时电泳,转移缓冲液的配方为:25mmol/L Tris,192mmol/L Glycine,20%甲醇,将蛋白转移至硝酸纤维膜上,电泳结束后,取出硝酸纤维膜,洗涤液TBST清洗后浸入封闭液中37℃1小时,TBST室温洗3次,每次5min,分别加入兔抗人GDF-8多克隆抗体和鼠抗His单克隆抗体,37℃孵育1小时,TBST洗3次,分别加入羊抗兔IgG-AP和兔抗鼠IgG-AP,37℃孵育1小时,TBST洗3次,再用TBS洗3次,硝酸纤维膜浸入显色液中,室温避光显色适当时间,蒸馏水冲洗终止反应;After the SDS-PAGE is over, remove the gel, put the gel near the cathode side, and the nitrocellulose membrane near the anode side, and electrophoresis in the pre-cooled transfer buffer at 100V constant voltage for 1 hour. The transfer buffer formula is: 25mmol /L Tris, 192mmol/L Glycine, 20% methanol, transfer the protein to the nitrocellulose membrane, after electrophoresis, take out the nitrocellulose membrane, wash with the washing solution TBST and immerse in the blocking solution at 37°C for 1 hour, wash 3 times at room temperature with TBST , 5min each time, add rabbit anti-human GDF-8 polyclonal antibody and mouse anti-His monoclonal antibody, incubate at 37°C for 1 hour, wash 3 times with TBST, add goat anti-rabbit IgG-AP and rabbit anti-mouse IgG-AP respectively , incubate at 37°C for 1 hour, wash 3 times with TBST, then wash 3 times with TBS, immerse the nitrocellulose membrane in the color developing solution, keep the color at room temperature for an appropriate time in the dark, rinse with distilled water to terminate the reaction; 蛋白透析复性Protein dialysis refolding 收集色谱层析柱的洗脱液,采用尿素浓度梯度透析方法透析纯化蛋白,尿素浓度梯度为8M→4M→2M→H2O溶液,透析上清液中的蛋白作为myostatin的蛋白疫苗;Collect the eluate from the chromatographic column, and use the urea concentration gradient dialysis method to dialyze and purify the protein. The urea concentration gradient is 8M→4M→2M→H 2 O solution, and the protein in the dialyzed supernatant is used as the protein vaccine of myostatin; 二、myostatin的基因疫苗制备2. Genetic vaccine preparation of myostatin 1)重组质粒pVAC-TT-Ms的构建1) Construction of recombinant plasmid pVAC-TT-Ms 以pQE-TT-Ms为模板,应用合成引物1和引物2将pQE-TT-Ms 5’端和3’端的酶切位点分别突变为BamH I和EcoR I;Using pQE-TT-Ms as a template, synthetic primers 1 and 2 were used to mutate the restriction sites at the 5' and 3' ends of pQE-TT-Ms into BamH I and EcoR I, respectively; PCR扩增:取1μLpQE30-TT-Ms质粒为模板,加入10×PCR缓冲液5μl,25mmol/L MgCl2 5Ml,25mmol/L 4×dNTPs 1μl,25μM的引物2、3各1μl,加入TaqDNA聚合酶1μl,用水补足体积至50μl;然后进行PCR反应,PCR扩增的循环参数为:95℃预变性5min后,按下列参数循环30次:PCR amplification: Take 1 μL pQE30-TT-Ms plasmid as template, add 5 μl of 10×PCR buffer, 25mmol/L MgCl 2 5Ml, 25mmol/L 4×dNTPs 1μl, 25μM primers 2 and 3 each 1μl, add TaqDNA polymerase 1 μl, make up the volume to 50 μl with water; then carry out PCR reaction, the cycle parameters of PCR amplification are: after pre-denaturation at 95°C for 5 minutes, cycle 30 times according to the following parameters: 94℃变性1min,56℃退火1min,72℃延伸1min,最后一个循环72℃延伸10min;Denaturation at 94°C for 1 min, annealing at 56°C for 1 min, extension at 72°C for 1 min, and last cycle of extension at 72°C for 10 min; PCR产物用1.5%琼脂糖凝胶电泳分离后,回收目的片段;用BamH I和EcoRI双酶切pVAC1-cms质粒和回收的基因片段,回收的质粒大片段与TT-Ms片段连接,连接产物转化感受态细胞DH5α,挑取阳性克隆,于LB培养基中培养过夜,提取质粒DNA,经酶切鉴定和DNA序列分析,将测序正确者命名为pVAC-TT-Ms;After the PCR product was separated by 1.5% agarose gel electrophoresis, the target fragment was recovered; the pVAC1-cms plasmid and the recovered gene fragment were double-digested with BamHI and EcoRI, and the large fragment of the recovered plasmid was ligated with the TT-Ms fragment, and the ligated product was transformed Competent cell DH5α, pick positive clones, culture overnight in LB medium, extract plasmid DNA, identify by enzyme digestion and DNA sequence analysis, and name the correct sequenced pVAC-TT-Ms; 2)重组质粒的扩增2) Amplification of recombinant plasmids 重组质粒pVAC-TT-Ms,转化感受态细胞DH5α,挑取单克隆培养过夜,次日清晨,按1∶100的比例接种于10ml含zeocin抗生素的LB培养基中培养8h,再按1∶100的比例接种于200ml含zeocin抗生素的LB培养基,摇菌25h,200rpm,37℃,收菌;Transform the competent cells DH5α with recombinant plasmid pVAC-TT-Ms, pick a single clone and culture overnight, in the morning of the next day, inoculate in 10ml LB medium containing zeocin antibiotic at a ratio of 1:100 and culture for 8 hours, then culture at a ratio of 1:100 Inoculate in 200ml LB medium containing zeocin antibiotic, shake the bacteria for 25h, 200rpm, 37℃, and harvest the bacteria; 3)宿主菌的收获和碱裂解3) Harvest and alkaline lysis of host bacteria 于4℃以4000rpm离心20分钟,弃上清,将细菌沉淀重悬于100ml用冰预冷的STE中;Centrifuge at 4000rpm at 4°C for 20 minutes, discard the supernatant, and resuspend the bacterial pellet in 100ml ice-cold STE; 将冼过的500ml培养物的细菌沉淀物重悬于10ml或18ml的溶液I中,高压灭菌15min,贮存于4℃;加2ml溶菌酶溶液,再加20ml或40ml溶液II,盖紧瓶盖,缓缓颠倒离心瓶数次,充分混匀内容物,于室温放置5~10min;加15nl用冰预冷的溶液III封住瓶口,摇动离心瓶数次以混匀内容物,此时应不再出现分明的两个液相;置冰上放10min,应形成一白色絮状沉淀;于0℃放置后所形成的沉淀应包括染体DNA、高分子量RNA和钾-SDS-蛋白质-膜复合物;Resuspend the washed 500ml bacterial sediment in 10ml or 18ml of solution I, autoclave for 15min, store at 4°C; add 2ml of lysozyme solution, add 20ml or 40ml of solution II, and cap the bottle tightly , slowly invert the centrifuge bottle several times, fully mix the contents, and place at room temperature for 5-10 minutes; add 15nl of ice-precooled solution III to seal the bottle mouth, shake the centrifuge bottle several times to mix the contents, at this time should Two distinct liquid phases no longer appear; put it on ice for 10 minutes, and a white flocculent precipitate should form; after standing at 0°C, the precipitate formed should include chromosomal DNA, high molecular weight RNA, and potassium-SDS-protein-membrane Complex; 所述的溶液I为50mmol/L葡萄糖,pH8.0的25mmol/L Tris·Cl,pH8.0的10mmol/LEDTA;Described solution I is 50mmol/L glucose, the 25mmol/L Tris·Cl of pH8.0, the 10mmol/LEDTA of pH8.0; 所述的溶液II为0.2mol/LNaOH,1%SDS;Described solution II is 0.2mol/LNaOH, 1%SDS; 所述的溶液III为5mol/L乙酸钾60ml,冰乙酸11.5ml,水28.5ml;Described solution III is 60ml of 5mol/L potassium acetate, glacial acetic acid 11.5ml, water 28.5ml; 于4℃以4000rpm离心15min,自然停转;如果细菌碎片贴壁不紧,可以5000rpm再度离心20min,然后小心将上清全部转到另一瓶中,弃去残留在离心管内的粘稠状液体;上清过滤至一250ml离心瓶中,加0.6体积的异丙醇,充分混匀,于室温放置10min;于室温以500rpm离心15分钟,回收核酸;小心倒掉上清,敞开瓶口倒置离心瓶使残余上清液流尽,室温用70%乙醇洗涤沉积管壁;倒出乙醇,用与真空装置相联的巴斯德吸管吸出附于瓶壁的所有液滴,于室温将瓶倒置放在纸巾上,使最后残余的乙醇挥殆尽,用pH8.0的3ml TE溶解核酸沉淀;Centrifuge at 4000rpm at 4°C for 15min, stop naturally; if the bacterial fragments are not tightly attached to the wall, centrifuge again at 5000rpm for 20min, then carefully transfer all the supernatant to another bottle, and discard the viscous liquid remaining in the centrifuge tube ;filter the supernatant into a 250ml centrifuge bottle, add 0.6 volume of isopropanol, mix thoroughly, and place at room temperature for 10 minutes; centrifuge at 500rpm at room temperature for 15 minutes to recover nucleic acid; carefully pour off the supernatant, open the bottle and invert and centrifuge Drain the remaining supernatant from the bottle, wash the wall of the deposition tube with 70% ethanol at room temperature; pour off the ethanol, suck out all the droplets attached to the wall of the bottle with a Pasteur pipette connected to a vacuum device, and place the bottle upside down at room temperature On paper towels, evaporate the last remaining ethanol, and dissolve the nucleic acid precipitate with 3ml TE of pH 8.0; 4)质粒的纯化4) Plasmid purification 将核酸溶液转入15ml Corex管中,再加3ml用冰预冷的5mol/L LiCl溶液,充分混匀,于4℃下以10000rpm离心10min;将上清转移到另一30ml Corex管内,加等量的异丙醇,充分混匀,于室温以10000rpm离心10min,回收沉淀的核酸;Transfer the nucleic acid solution into a 15ml Corex tube, add 3ml of 5mol/L LiCl solution pre-cooled with ice, mix thoroughly, and centrifuge at 10000rpm at 4°C for 10min; transfer the supernatant to another 30ml Corex tube, add, etc. A small amount of isopropanol, mixed thoroughly, and centrifuged at 10000rpm for 10min at room temperature to recover the precipitated nucleic acid; 去掉上清,敞开管口,将管倒置以使最后残留的液滴流尽,于室温用70%乙醇洗涤沉淀及管壁,流尽乙醇,用与真空装置相连的巴斯德吸管吸去附于管壁的所有液滴,敞开管口并将管倒置,在纸巾上放置几分钟,以使最后残余的乙醇蒸发殆尽;Remove the supernatant, open the mouth of the tube, turn the tube upside down so that the last remaining droplets flow out, wash the precipitate and the tube wall with 70% ethanol at room temperature, drain the ethanol, and use a Pasteur pipette connected to a vacuum device to remove the adsorption. To remove any droplets on the tube wall, open the spout and invert the tube, and let it sit on a paper towel for a few minutes to allow the last remaining ethanol to evaporate; 用500μl含无DNase的胰RNase20μg/ml pH8.0的TE溶解沉淀,将溶液转到一微量离心管中,于室温放置3min;加500μl含13%(w/v)聚乙二醇PEG 8000的1.6mol/LNaCl,充分混合,用微量离心机于4℃以12000g离心5min,以回收质粒DNA;吸出上清,用pH80的400μlTE溶解质粒DNA沉淀;用酚、酚:氯仿、氯仿各抽1次;将水相转到另一微量离心管中,加100μl 10mol/L乙醇铵,充分混匀,加2倍体积乙醇,于室温放置10min,于4℃以12000g离心5min,以回收沉淀的质粒DNA;吸去上清,加200μl处于4℃以12000g离心2min;吸去上清,敞开管口,使乙醇蒸发殆尽;用pH8.0的500μlTE溶解沉淀1∶100稀释后测量OD260/OD280,计算质粒DNA的浓度,其中1OD260=50μg质粒DNA/ml,然后将DNA贮于-20℃,作为myostatin的基因疫苗。Dissolve the precipitate with 500 μl TE containing DNase-free pancreatic RNase 20 μg/ml pH8.0, transfer the solution to a microcentrifuge tube, and place it at room temperature for 3 minutes; add 500 μl of PEG 8000 containing 13% (w/v) 1.6mol/L NaCl, mix thoroughly, and centrifuge at 12,000g for 5min at 4°C in a microcentrifuge to recover plasmid DNA; aspirate the supernatant, and dissolve the plasmid DNA precipitate with 400μl TE of pH 80; use phenol, phenol:chloroform, and chloroform to pump once each ;Transfer the water phase to another microcentrifuge tube, add 100μl 10mol/L ethanolammonium, mix thoroughly, add 2 times the volume of ethanol, let stand at room temperature for 10min, and centrifuge at 12000g for 5min at 4°C to recover the precipitated plasmid DNA ; Aspirate the supernatant, add 200μl and centrifuge at 12000g for 2min at 4°C; aspirate the supernatant, open the mouth of the tube to evaporate the ethanol; use 500μl TE of pH 8.0 to dissolve the precipitate 1:100 and measure OD 260 /OD 280 , calculate the concentration of plasmid DNA, where 1OD 260 =50 μg plasmid DNA/ml, and then store the DNA at -20°C as a gene vaccine for myostatin.

CN200610104728A 2006-10-13 2006-10-13 A kind of therapeutic vaccine of Myostatin specific antibody and preparation method thereof Expired - Fee Related CN100586476C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200610104728A CN100586476C (en) 2006-10-13 2006-10-13 A kind of therapeutic vaccine of Myostatin specific antibody and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN200610104728A CN100586476C (en) 2006-10-13 2006-10-13 A kind of therapeutic vaccine of Myostatin specific antibody and preparation method thereof

Publications (2)

Publication Number Publication Date
CN101057970A CN101057970A (en) 2007-10-24
CN100586476C true CN100586476C (en) 2010-02-03

Family

ID=38864373

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200610104728A Expired - Fee Related CN100586476C (en) 2006-10-13 2006-10-13 A kind of therapeutic vaccine of Myostatin specific antibody and preparation method thereof

Country Status (1)

Country Link
CN (1) CN100586476C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3340B1 (en) * 2010-05-26 2019-03-13 Regeneron Pharma Antibodies to human gdf8

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MSTN基因的研究进展. 张利媛等.草食家畜,第132期. 2006
MSTN基因的研究进展. 张利媛等.草食家畜,第132期. 2006 *
肌肉抑制素基因工程疫苗原型的研究. 马,毅.中国优秀博士论文网. 2005
肌肉抑制素基因工程疫苗原型的研究. 马毅.中国优秀博士论文网. 2005 *

Also Published As

Publication number Publication date
CN101057970A (en) 2007-10-24

Similar Documents

Publication Publication Date Title
ES2280115T3 (en) 2007-09-01 IMMUNOLOGICAL COMPOSITIONS TO MODULATE MYOSTATINE IN VERTEBRATED SUBJECTS.
HU219674B (en) 2001-06-28 Dna molecules encoding glucagon receptor, glucagon receptor peptides, monoclonal antibodies blocking the glucagon receptor and method for producing them
KR940004077B1 (en) 1994-05-11 Recombinantinhbin
WO1991016922A1 (en) 1991-11-14 Analogs of glycoprotein hormones having altered immunological characteristics, efficacy and/or receptor specificity
KR100335320B1 (en) 2002-09-13 Improved peptides, immunogenic compositions and vaccines or medical preparations for progesterone-releasing hormones, methods of immunizing animals, and their use as analogs and vaccines of luteinizing hormone-releasing hormone serial repeat peptides
CA2222947A1 (en) 1996-12-19 Inhibin compositions and methods of enhancing production performance
TWI250164B (en) 2006-03-01 Highly purified cytokine activating factor and methods of use
JPH05506447A (en) 1993-09-22 A method for enhancing the association of foreign peptides with class I MHC molecules on the surface of antigen-supplying cells with β↓2-microglobulin
JPH07509776A (en) 1995-10-26 Endonexin ■ derived polypeptide with hepatitis B virus receptor activity and its use in diagnostic and pharmaceutical compositions
CN100586476C (en) 2010-02-03 A kind of therapeutic vaccine of Myostatin specific antibody and preparation method thereof
CN101602809B (en) 2011-12-07 Antibody targeted complement inhibitor with anti-inflammatory action
JPH05507208A (en) 1993-10-21 nematode vaccine
CN102276725B (en) 2013-06-05 Cryptosporidium CTL and Th mixed multi-epitope gene and fusion protein and application
US20200071384A1 (en) 2020-03-05 Cyclic peptides for the treatment of graves' disease
DE60125959T2 (en) 2007-10-18 DISTINCTION BETWEEN GNRH-I AND GNRH-II
CN103547286B (en) 2016-10-19 A kind of composition of DNA vaccine for preventing and treat hepatitis B
CN1063109A (en) 1992-07-29 Improvement to hormone and associated materials
EP1578791B1 (en) 2008-03-12 Inclusion bodies for the oral vaccination of animals
CN102675424B (en) 2014-02-05 Polypeptide drug for resisting Hepatitis B virus X protein
US20220362359A1 (en) 2022-11-17 Dna vaccine capable of effectively treating and/or preventing type 1 diabetes and use thereof
DE68920735T2 (en) 1995-05-24 Peptides from the foot and mouth disease virus.
US5864008A (en) 1999-01-26 Peptides derived from foot-and-mouth disease virus, pharmaceutical compositions, and methods for using the peptides
CN110964119A (en) 2020-04-07 Anti-malarial dimeric immunoadhesin, pharmaceutical composition and use
CN100577212C (en) 2010-01-06 The function and application of E4BP4 gene in embryo implantation
KR100568193B1 (en) 2006-04-27 DNA vaccine containing epidemic F-Drogen virus epitope for the prevention of C-F

Legal Events

Date Code Title Description
2007-10-24 C06 Publication
2007-10-24 PB01 Publication
2007-12-19 C10 Entry into substantive examination
2007-12-19 SE01 Entry into force of request for substantive examination
2010-02-03 C14 Grant of patent or utility model
2010-02-03 GR01 Patent grant
2015-12-09 CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100203

Termination date: 20141013

2015-12-09 EXPY Termination of patent right or utility model